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ABSTRACT OF DISSERTATION 
ID3, ESTROGENIC CHEMICALS, AND THE PATHOGENESIS OF TUMOR -
LIKE PROLIFERATIVE VASCULAR LESIONS  
 
Vincent E. Avecilla 
Florida International University, 2017 
Miami, Florida 
Professor Quentin Felty, Major Professor 
Tumor-like proliferative vascular lesions manifest in several diseases such as 
peripheral arterial disease (PAD) and atherosclerosis (AS) after arterial injury. The 
cause of the vascular cell dysfunction in PAD patients is not known. Our recent 
novel discovery shows that inhibitor of differentiation 3 (ID3) is highly expressed in 
intimal lesions of clinical vascular disease samples. The central hypothesis of our 
study is: estrogenic chemical induced dysregulation of ID3 target genes is involved 
in the development of vascular disease. NHANES data analysis demonstrated 
higher geometric levels of all 6 PCB congeners in both PAD diagnosed participants 
and defined AS participants when compared to the rest of the population. Adjusted 
models showed association between higher exposure of PCBs, phthalates, BPA, 
and increased risk of PAD. Furthermore PCB153 was shown to have the highest 
geometric mean amongst all PCB congeners in both participants diagnosed with 
PAD and at risk of AS. Gene expression of ID3 & ID3 candidate targets in blood & 
tissue studies identified ID3 & ID3 candidate target genes as a driver of vascular 
 vii 
 
disease. Overlapping ID3 & ID3 candidate target genes included: ABCB6, ACP1, 
BYSL, CAD, CDH15, DCBLD2, DHRS3, DNMT1, ID3, MCM4, and NDUFA7. The 
ID3 target genes involved in the: focal adhesion pathway were ACTN1, COL1A2, 
COL3A1, COL6A1, CTNNB1, IBSP, ID3, ITGA8, and MYL2; ECM-receptor 
interaction were COL1A2, COL3A1, COL6A1, IBSP, ID3, and ITGA8; oxidative 
phosphorylation pathway ATP5D, ATP5H, ATP6V0B, ATP6V0D1, ATP6V1B2, 
COX5A, COX7C, COX8A, CYC1, ID3, NDUFA1, NDUFA7, NDUFS4, NDUFV1, 
NDUFV2; and cell cycle pathway ANAPC10, ATM, CDKN2B, E2F5, MCM3, and 
MCM4. In summary our results showed an association between exposure to PCBs, 
phthalates, BPA, and increased risk of PAD and AS, and possible molecular 
mechanisms of interaction of ID3 target genes and estrogenic chemicals involved 
in PAD and AS. 
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CHAPTER I 
INTRODUCTION 
Systematic & pulmonary vascular biologists have inclined to position their 
particular research in different ways. This distinction is readily implicit in light of 
their predominantly different interests. Those that are engaged in research on 
pulmonary circulation have often centered their attention on pulmonary arterial 
hypertension, a life threatening condition that affect your arteries which go from 
your heart to your lungs. Oppositely systematic circulation have traditionally 
focused on the pathogenesis of atherosclerosis, a common disease that affects 
large arteries and in which the lipid metabolism features chiefly have been 
explored in mechanisms in restenosis after angioplasty. These divergent pathways 
intersect at obliterative and proliferative vascular diseases which commonly disrupt 
the blood vessel. These two types of vascular diseases certainly have similar 
elements such as interactions between the vessel wall and various components of 
blood. Others involve interactions between the smooth muscle of the media & 
endothelial lining but while exasperating and preserving mechanisms have been 
established in both, the unique perturbations that initiates these processes remains 
uncertain.  
A class of proteins that have been seen to be involved with these types of 
vascular diseases are ID proteins (ID1, ID2, ID3, and ID4). Their names relate to 
their ability to regulate the programming of cell fate determination and 
differentiation in various types of cells through normal development and adult life 
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(Lasorella et al., 2014). The ID3 gene was first identified as a serum-inducible 
immediate early gene in an established murine fibroblastic cell line (Christy et al., 
1991). Previous studies have demonstrated its involvement in various biological 
processes, including: tumor-induced angiogenesis, embryonic neurogenesis, 
osteogenesis, vascular smooth muscle cell proliferation, T & B cell development, 
and skeletal muscle differentiation (Atherton et al., 1996; Deed et al., 1996; 
Melnikova & Christy, 1996; Pan et al., 1999, Lyden et al., 1999; Rivera et al., 2000; 
Forrest et al., 2004; Maeda et al., 2004).  ID3 has been shown to be involved in 
various types of vascular diseases such as adult kidney injury (AKI) which is 
involved in loss of capillary function and vascular remodeling in the luteum (CL), a 
temporary endocrine organ that is involved in the production of high levels of 
progesterone and moderate levels of estradiol, atherosclerotic disease, and 
pulmonary hypertension (Lee et al., 2014; Yang et al., 2013; Nio-Kobayashi et al., 
2012; Doran et al., 2010). Expression and function of the protein is under several 
multifaceted layers of regulation and therefore can provide beneficial targets for 
therapeutic interventions.  
Vascular diseases can manifest from a combination of both environmental 
& molecular determinants. Progression in machine/deep learning and genomic 
technologies have facilitated investigators to generate hypotheses regarding the 
integration & contribution of genetic factors at a rapid pace. However, the 
assessment of specific and numerous environmental pollutants and their 
interactions with the genome has not. There still lacks methodologies to 
comprehensively analyze and interpret several multifaceted environmental & 
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cellular constitutes to disease and human health. One environmental determinant 
that has been demonstrated to show association with ID3 are chemicals commonly 
known as estrogenic or endocrine disrupting chemicals (EDCs). These chemicals 
are synthetic and natural that have the ability to disrupt metabolic pathways by 
either mimicking or blocking endogenous hormones and modifying hormone 
function (Roy et al. 1997). Many EDCs are considered highly carcinogenic and 
include an assortment of chemicals such as industrial compounds, by-products of 
industrial procedures, chemicals that are used in the manufacturing of plastics, and 
pesticides. Of specific concern to public health professionals are agents that are 
persistent in the environment that are hormonally active, greatly lipophilic, amplify 
within the food chain, and are readily bio-accumulative (Lyche et al., 2009; Meeker 
et al., 2009).  
Since many of these chemicals are used in numerous amounts of consumer 
products, exposure to EDCs through the general population is prevalent. Human 
exposure to EDCs may result in different ways such as absorption through the 
skin, ingestion of contaminated food & water, and airborne inhalation (Balabanic 
et al., 2001). During the last decade multiple EDC exposure such as 
polychlorinated biphenyls (PCBs), bisphenol A (BPA), and phthalates have been 
detected in > 90% urine & blood samples collected from the general population of 
the United States (Silva et al., 2004; Calafat et al., 2008; Woodruff et al., 2011). 
EDCs that are persistent today in the environment have shown properties of 
endocrine disruption. PCBs have demonstrated to have estrogenic and anti-
estrogenic properties contingent on the congener. Previously PCB exposure has 
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been shown to be associated with cardiovascular disease (Perkins et al. 2016). 
Higher exposure of urinary phthalates furthermore have been demonstrated to be 
associated with hypertension in childhood (Trasande et al. 2013). Exposure to BPA 
has demonstrated to result in atherosclerosis, altered cardiac remodeling, and 
changes in blood pressure in rodents (Gao & Wang, 2014). Although there are 
vast amount of EDCs in the environment the most extensively studied EDCs 
include polychlorinated biphenyls, phthalates, and bisphenol A.  
The existing disciplines of studying environmental pollutants & molecular 
determinants of health include epidemiology, molecular/genetic biology, & 
toxicology which function on population, bioinformatics, and molecular scales, 
respectively. This dissertation proposes methodology in all of these disciplines 
emphasizing the framework of environmental - and genomic - wide association 
studies through the utilization of public databases such as the National Health and 
Nutrition Examination Survey (NHANES) and NCBI Gene Omnibus Expression 
(GEO). The overachieving goals of this research was to first determine the 
association between exposure to these endocrine disrupting chemicals in a U.S. 
population diagnosed with vascular disease  and secondly; determine the role of 
ID3 in vascular-intimal lesion formation and investigate its activity via regulation of 
cell adhesion, extracellular matrix proteolysis, and cell growth. Documenting both 
exposure to EDCs among the U.S. population & associations with vascular disease 
and the role of ID3 in vascular-intimal lesions will help guide our understanding of 
the complexity of environmental molecular determinants in vascular disease.  
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HYPOTHESIS 
 
Estrogenic chemical induced dysregulation of ID3 target genes is involved in the 
development of vascular disease  
SPECIFIC AIMS 
Aim 1: Collect environmental exposure data from National Health and Nutrition 
Examination Survey (NHANES) database and gene expression data from the 
Gene Expression Omnibus (GEO) database 
Aim 2: Investigate the association between exposure to estrogenic chemicals and 
vascular disease (peripheral arterial disease) 
Aim 3: Identify ID3 regulated molecular gene networks 
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disrupting chemicals to pathophysiological aspects of chronic disease 
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Abstract 
 
The overwhelming increase in the global incidence of obesity and its associated 
complications such as insulin resistance, atherosclerosis, pulmonary disease, and 
degenerative disorders including dementia constitutes a serious public health 
problem. The Inhibitor of DNA binding/Differentiation-3 (ID3), a member of the ID 
family of transcriptional regulators, has been shown to play a role in adipogensis 
and therefore ID3 may influence obesity and metabolic health in response to 
environmental factors. This review will highlight the current understanding of how 
ID3 may contribute to complex chronic diseases via metabolic perturbations. 
Based on the increasing number of reports that suggest chronic exposure to and 
accumulation of endocrine disrupting chemicals (EDCs) within the human body are 
associated with metabolic disorders, we will also consider the impact of these 
chemicals on ID3. Improved understanding of the ID3 pathways by which exposure 
to EDCs can potentiate complex chronic diseases in populations with metabolic 
disorders (obesity, metabolic syndrome, and glucose intolerance) will likely provide 
useful knowledge in the prevention and control of complex chronic diseases 
associated with exposure to environmental pollutants. 
 
Keywords: endocrine disrupting chemicals, ID3, metabolic disorders, chronic 
disease 
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Introduction 
Inhibitor of DNA binding/Differentiation-3 is a member of the ID family of helix-loop-
helix proteins encoded by an immediate-early gene responsive to mitogenic 
signals and oxidative stress. ID3 functions as a transcriptional regulator known to 
prevent stem cell differentiation and promote cell cycle progression. An increasing 
body of evidence suggests that ID3 may be involved in metabolic perturbations 
characterized by insulin resistance, hyperglycemia, abdominal obesity, 
dyslipidemia, and hypertension. Interactions across multiple organ systems that 
contribute to metabolic perturbations presents a challenge to ongoing research 
attempting to elucidate biological mechanisms of chronic disease associated with 
metabolic health. For instance, insulin resistance and systemic low-grade 
inflammation result from complex interactions between the vasculature, metabolic 
tissue, and immune cells. With regard to these interactions, it is noteworthy that 
ID3 plays a significant role in vasculogenesis, energy metabolism, and in the 
development of the immune system. In the vasculature, ID3 is essential to 
embryonic vasculogenesis and endothelial cell activation (Sakurai et al. 2004; 
Felty and Porther. 2008; Eelen et al. 2015). Given that metabolic perturbations are 
observed in endothelial cells from diseased vasculature (He et al. 2014), ID3 may 
mediate endothelial dysfunction often found in individuals with metabolic 
syndrome. In addition to the vasculature, ID3 function spans to metabolic tissue 
and immune cells. In vivo studies have demonstrated that ID3 mediates high fat 
diet induced obesity and promotes obesity-induced inflammatory macrophage 
accumulation (Doran et al. 2008; Cutchins et al. 2012). Thus, we intend to discuss 
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the current understanding of how ID3 may influence chronic diseases associated 
with metabolic perturbations. Since adipose tissue is an endocrine organ as well 
as a metabolic organ, exposure to endocrine disrupting chemicals (EDCs) may 
also contribute to metabolic perturbations associated with chronic disease. EDCs 
are mostly synthetic chemicals ubiquitously found in our environment that act by 
altering hormone action. Estrogenic EDCs such as diethylstilbestrol (DES), 
bisphenol A (BPA), estrogenic polychlorinated biphenyls (PCBs), and phthalates 
have been implicated to interfere with metabolic health during critical periods of 
development and into adulthood. Epidemiological studies have reported 
associations between exposures to EDCs and metabolic syndrome (Swedenborg 
et al. 2003; Hatch et al. 2010; Casals-Casas and Desvergne. 2011). Based on our 
recent findings that showed ID3 dependent endothelial cell activation by exposure 
to estrogenic PCB congener 153 (Felty. 2011; Das and Felty. 2014), we will also 
discuss how low dose EDC exposure from the environment may potentiate 
complex chronic disease in populations with metabolic disorders (obesity, 
metabolic syndrome, and glucose intolerance) via ID3. A better understanding of 
interactions between ID3 and EDC is critical in deepening our understanding of 
how environmental factors modify chronic disease risk and health outcomes. 
Further study in these areas may reveal novel or more effective therapeutic 
modalities as well as provide prevention and control strategies of complex chronic 
diseases associated with exposure to EDCs. 
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Inhibitor of DNA binding/Differentiation-3 (ID3) 
 
Structure and Function. The ID (Inhibitor of DNA binding/Differentiation) family 
of small proteins consists of four genes (ID1-ID4). The four members of the ID 
family share extensive amino acid sequence homology (69-78%) within their helix-
loop-helix (HLH) domain (Lyden et al. 1999, Yang et al. 2014), but the remaining 
parts of the proteins are non-related. Experimental studies in genetically 
engineered mice have revealed the importance of ID3 in embryonic development 
and cell differentiation. ID3 gene knockout mice are viable, however, they have 
demonstrated defects in immune cell differentiation (Pan et al. 1999; Lasorella et 
al. 2014). In contrast, double ID1/ID3 knockout mice showed abnormal 
vascularization of the brain (Poulsen et al. 2001), neuronal differentiation, and 
cardiac defects (Fraidenraich et al. 2004) that were embryonically lethal. 
Resistance to tumor angiogenesis was reported in mice deficient in 1-3 alleles of 
ID1/ID3 gene knockout combination (Lyden et al. 1999). ID3 is highly expressed 
in embryonic tissue, but declines as cells differentiate (Lyden et al. 1999). In adult 
tissues, the expression of ID3 is context specific and tends to be highest in 
proliferating and undifferentiated cells. ID3 expression has been reported to be 
induced by diverse stimuli in many cell types (Lim and Wu. 2005).  
 The ID3 gene was initially identified as a serum-inducible immediate-early 
gene in mouse fibroblasts that peaks transcriptionally at 1h (Lasorella et al. 2001; 
Lasorella et al. 2014). Subsequently, ID3 expression has been reported to be 
biphasic with maximal stimulation at 1h following a second burst at 24h as in the 
case of tissue regeneration after injury. We and others have shown that ID3 
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expression is redox sensitive (Felty and Porther. 2008; Mueller et al. 2012) 
specifically, we have shown that vascular endothelial cells exposed to either 17β-
estradiol (E2) or the estrogenic PCB congener 153 (PCB153) resulted in increased 
ID3 expression, protein phosphorylation, and endothelial neovascularization. 
Treatment with reactive oxygen species scavengers inhibited estrogenic chemical 
induced neovascularization (Das and Felty. 2014; Das and Felty. 2014). 
Proteasomes reportedly degrade ID3 by an ubiquitin dependent mechanism. The 
protein half-life of ID3 has been demonstrated to be approximately 20 min in 
HEK293 cells (Yang and Morrell. 2014). In mammals, ID protein-protein 
interactions occur via the HLH-motif in which ID proteins dimerize and block the 
DNA binding activity of basic HLH transcription factors, such as a group of E 
proteins (E12/E47, E2-2, HEB) encoded by the TCF3, TCF4, and TCF12 gene, 
respectively. Among these E proteins, ID3 has been most often reported to interact 
with E12/E47 (Loveys et al. 1996). The E proteins are basic HLH transcription 
factors that bind to the E-box consensus sequence (CANNTG) in the promoter of 
target genes. ID3 plays an important role in cell proliferation via its interactions with 
E proteins. For example, E proteins have been shown to bind the E-box sequence 
in the promoter of the cyclin dependent kinase inhibitor p21Cip1 and activate its 
transcription (Liu et al. 2004). The level of p21Cip1 is elevated in quiescent cells 
where it acts as a suppressor of cell proliferation (Sherr and Roberts. 1995). In the 
context of the cell cycle, ID3 promotes cell cycle progression by the inhibition of 
p21Cip1 expression (Forrest and McNamara. 2004). Specifically, ID3 protein-protein 
interactions with E proteins can disrupt their ability to bind gene promoters and 
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thereby blocks transcriptional activation by these factors. ID3 has been shown to 
inhibit E proteins from activating the p21Cip1 promoter in proliferating vascular cells 
(Taylor et al. 2006). Thus, ID3 has been frequently described as a dominant 
negative inhibitor of E proteins. Although ID proteins have been shown to function 
as dominant negative transcriptional regulators of E proteins, there may be 
circumstances by which ID3 acts as a positive transcriptional regulator. ID3 has 
been shown to regulate the binding of Transcription Factor 3 (TCF3) to the E-box 
motif in target gene promoters (Langlands et al. 1997). TCF3 has been reported 
to repress the expression of pluripotency genes OCT4, SOX2, and NANOG that 
contribute to cell differentiation (Lasorella et al. 2014). Our research has shown 
that ectopic overexpression of ID3 increased OCT4 and SOX2 expression in 
endothelial cells as well as resulted in a population of cells that were positive for 
the molecular stemness signature CD133+ VEGFR3+ CD34+ (Felty et al. 2015). 
These endothelial stem cells were morphologically differentiated into smooth 
muscle cells and neuron cells. Based on these lines of evidence, ID3 maintains 
cells in an undifferentiated or non-committed state by preventing the repression of 
pluripotency factors by TCF3. Hence, it is also plausible for ID3 to function as a 
positive regulator of gene transcription. In lieu of a recent report that showed ID3 
to modulate genes essential for maintaining genome integrity during cell division 
(Ji et al. 2011) a dual regulatory role of ID3 in both positive and negative gene 
transcription expands its influence as shown in Figure 1.1. ID3 protein-protein 
interactions are not exclusive to E-proteins as ID proteins have also been reported 
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to bind to proteins that do not contain the HLH motif such as caveolin-1 (Zhang et 
al. 2007).  
Figure 1.1 ID3 transcriptional regulation. Scheme illustrating how ID3 can repress expression of p21 gene 
(upper panel) or activate gene expression of embryonic transcription factors (lower panel).  
 
ID3 and Metabolic Syndrome (MetS) 
 There has been increasing evidence that ID3 plays a role in adipogenesis. 
ID3 through adiponectin is considered to improve β-cell function, circulating lipids, 
and insulin sensitivity levels (Arita et al.1999; Steinberg and Kemp. 2009). ID3 
inhibits transcriptional activity of E47 in undifferentiated pre-adipocytes (Doran et 
al. 2008). ID3 negatively inhibits the FAS (fatty acid synthase) promoter via SREP-
1c in adipose tissue. ID3 furthermore plays a role in blood glucose, which if 
dysregulated can lead to insulin resistance. In human islet cells ID1 and ID3 mRNA 
levels are increased with addition of glucose (Wice et al. 2001). The induction of 
ID1 and ID3 expression, insulin secretion, and gene transcription suggests that 
IDs may play a role in promoting β-cell function (Wice et al. 2001, Lee et al. 2011).  
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ID3 & Endocrine Disrupting Chemicals Influence Metabolic Perturbation 
 Metabolic Syndrome (MetS) and its associated complications such as 
insulin resistance, abdominal obesity, dyslipidemia, and hypertension contribute to 
chronic diseases including cardiovascular disease (CVD), type 2 diabetes, cancer, 
and chronic kidney disease (CKD). Some studies have shown the prevalence of 
MetS in the United States at approximately 34% of the adult population (Ford et al. 
2002). MetS is an illness of energy consumption and storage which is a diagnosis 
of the co-occurrence of a minimum of three of the following medical conditions: 
abdominal obesity, high triglyceride levels, low HDL cholesterol levels, high fasting 
blood sugar, and high blood pressure. The molecular mechanisms of MetS are not 
fully understood. Most patients are older, sedentary, obese, and have a certain 
amount of insulin resistance. Important factors that are associated with MetS can 
include aging, diet, sedentary behavior, genetics, excessive alcohol use, or low 
physical activity (Poulsen et al. 2001; Pollex and Hegele. 2006; Malik et al. 2010; 
Edwardson et al. 2012). MetS appears to have three conceivable etiological 
groupings: obesity and disorders of adipose tissue; insulin resistance; and a 
collection of independent factors (ex: molecules of hepatic, vascular, and 
immunologic origin).  
 Inflammatory factors produced during obesity are a major pathway for 
developing metabolic perturbation which can lead to MetS. Experimental studies 
have demonstrated ID3 to be a key regulator of Monocyte chemoattractant protein-
1 (MCP-1) (Kapla et al. 2015). MCP-1 is a well-known chemokine impacted by 
MetS (Panee. 2012). ID3 has also been reported to regulate the production 
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of interleukins IL-5, IL-6, IL-8, and IL-10 (Jin et al. 2011; Kuo et al. 2011; Perry et 
al. 2012).The induction of these chemokines have been observed in population 
studies of obesity and/or MetS. ID3 is also an oxidative stress regulated gene 
which may provide a positive feedback pathway in response to metabolic 
perturbations (Mueller et al. 2002; Felty and Porther. 2008). Taken together, these 
lines of evidence provide the basis for how ID3 can participate in metabolic 
perturbations via controlling the expression of inflammatory factors involved in 
obesity and/or MetS. A growing number of reports implicate endocrine-disrupting 
chemicals (EDCs) as an environmental factor that contributes to the occurrence of 
MetS. We performed a comprehensive search in the Comparative Toxicogenomic 
Database (CTD) to identify known ID3 and EDC interactions with results shown in 
Table 1 (Mattingly et al. 2004). 
  Table 1. ID3 and Endocrine Disrupting Chemicals (EDCs) 
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Table 1. ID3 and Endocrine Disrupting Chemicals (EDCs). ID3 and endocrine disrupting chemical 
interaction created via Comparative Toxicogenomic Database (CTD).  
  
 
 
 Adipose tissue is highly connected to steroid hormones (estrogens, 
androgens, and glucocorticoids) and maintains a close relationship with the 
immune system via adipokines. Endocrine disruption can interfere with the 
creation, discharge, breakdown, elimination, and imitation of natural hormones (Jin 
et al. 2013). EDCs can be cataloged into multiple groupings such as dioxins, 
organotins, plastics, and pesticides. The increased presence of EDCs in the 
environment may help explain the incidence of metabolic disorders and associated 
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complications. EDCs are found in everyday products (including food, plastic 
bottles, metal cans, toys, cosmetics, & pesticides) and used in the manufacture of 
food. Exposure to EDCs may regulate inflammatory factors via ID3. TCDD and 
PCB congeners have been shown to up-regulate MCP-1 expression (Kirkley and 
Sargis. 2014). Bisphenol A exposure has been reported to increase IL-6 (Aremma 
et al. 2016). Population studies furthermore have reported an association between 
bisphenol-A plasma levels and pro-inflammatory cytokines including IL-6 
(Savastano et al. 2015). Besides inflammation, ID3 may contribute to other risk 
factors of MetS such as angiogenesis, adipose tissue, blood glucose levels, and 
insulin resistance. PCBs have been associated with MetS in epidemiological 
studies (Uemura et al. 2009). In the mouse model, PCB153 has been shown to 
produce significant metabolic changes when administered with a high fat diet that 
were consistent with worsened obesity and nonalcoholic fatty liver disease 
pathology (Wahlang et al. 2013). ID3 may contribute to MetS via visceral fat 
expansion that was demonstrated in mice fed a high-fat diet (Cutchins et al. 2012).
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ID3 deficiency resulted in greater energy expenditure and higher metabolic rate in 
mice at rest. With respect to metabolic disorders involving high glucose levels; ID3 
may be impacted because it was shown to be regulated by glucose in pancreatic 
islet β-cells (Wice and Permutt. 2001) and under chronic hyperglycemic conditions. 
ID family proteins were stabilized by which in turn activated metabolic genes 
(Gronning et al. 2006). Since a causal link of diabetes and vascular disease is 
chronic hyperglycemia, ID3 may also contribute to metabolic perturbations from 
high blood glucose levels. More importantly, however, is that mitochondrial 
reactive oxygen species (ROS) produced by vascular endothelial cells under 
hyperglycemic conditions may share a pathway similar to environmental toxicant 
induced oxidative stress which converges on ID3. PCBs have been reported to 
have estrogenic activity (Bitman and Cecil. 1970; Meek and Finch. 1999; Tavolari 
et al. 2006; Davey et al. 2007). PCB153 is an agonist for the pregnane X receptor 
(PXR) and the constitutive androstane receptor (CAR) which exert their effects on 
energy metabolism through gene regulation (Wada et al. 2009). Hence, 
dysregulation of these receptors by EDCs may contribute to PCB-induced 
metabolic perturbations. Several epidemiological studies have reported the 
association of PCB exposure with the increased risk of cardiovascular disease 
(Hay and Tarrel. 1997; Gustavsson and Hogstedt. 1997; Tokunaga and Kataoka. 
2003; Sergeev and Carpenter. 2005; Goncharov et al. 2011). Since cardiovascular 
disease is a chronic disease affected by metabolic perturbations, we investigated 
the effects of PCB153 exposure on ID3 in vascular cells. Based on known PCB 
blood levels from occupational exposure, we showed a significant increase in 
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PCB153-induced vascularization at doses of 10-100 ng/ml which was ID3 
dependent (Felty. 2011). We have shown that PCB-induced ROS mediated a 
highly branched neo-vascular phenotype depended on ID3 and Pyk2 (Das and 
Felty. 2014). Because the level of ID3 protein is determined by the rates of protein 
synthesis and protein degradation, we tested if PCB153 treatment affected ID3 
protein synthesis. We showed that estrogenic chemical induced ID3 did not 
depend on protein synthesis, instead PCB153 treatment increased ID3 protein 
stability in endothelial cells. The role of phosphorylation in the regulation of ID3 
protein stability is not known. A search with the PhosphoMotif finder program 
revealed that ID3 had 38 serine kinase/phosphatase motifs and 8 tyrosine 
kinase/phosphatase motifs (Amanchy et al 2007). We reported that both E2 and 
PCB153 induced ID3 phosphorylation. E2 treatment stabilized ID3 protein during 
the 1-6h treatment time points and increased phosphorylated ID3 levels (Das and 
Felty. 2014, Das and Felty. 2014). It was noteworthy that we showed data of ID3 
tyrosine phosphorylation by PCB153 treatment which was confirmed by MALDI-
TOF MS/MS spectra data. Our findings revealed phosphorylated amino acids Tyr-
11 and Tyr-48 in peptides from ID3. Interestingly, Tyr-48 is positioned in the helix-
loop-helix motif that is essential for protein binding. Currently, it is not clear whether 
PCB153-induced phospho-ID3 leads to protein-protein interactions that may 
prevent its degradation; however, our findings demonstrated that ID3 is a target of 
post-translational modifications by the endocrine disruptor PCB153 in vascular 
endothelial cells. Based on these lines of evidence, estrogenic chemical-induced 
ID3 signaling contributes to hyperplastic vascular lesions. This vascular cell 
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dysfunction may be a pathway by which EDCs and ID3 contribute to cardiovascular 
disease (Felty and Porther. 2008). Based on these findings, we propose that ID3 
is a target of EDCs that can activate inflammatory and energy pathways 
susceptible to metabolic perturbation during chronic disease pathogenesis. In the 
next section, we intend to discuss the current mechanistic understanding of how 
ID3 may influence chronic diseases associated with metabolic perturbations. 
 
ID3 & Disease Outcomes 
 
Vascular Diseases. ID3 involvement in vascular disease has been studied 
together with the lipoxygenase (12/15-LO) which is known to generate pro-
inflammatory changes in blood vessels that precede the development of 
atherosclerosis (Chakrabarti et al. 2009). 12/15-LO is an important mediator of 
VSMC growth and its growth-promoting effects were shown to be mediated by ID3 
transcription (Taylor et al. 2005). Increased expression of 12/15-LO in the vessel 
wall enhanced ID3-dependent cell proliferation, fibronectin deposition, and 
neointimal formation. Population based studies have found a SNP (single 
nucleotide polymorphisms) rs11574 in the coding region of the human ID3 gene 
associated with subclinical atherosclerosis in the Diabetes Heart study (Doran et 
al 2010). ID3 SNP rs11574 showed a significant association of coronary artery 
disease for caucasians and to a lesser extent in African Americans and Hispanics 
(Manichaikul et al. 2014).   
 Ectopic expression of ID3 in VSMC (vascular smooth muscle cells) 
regulates the cell-cycle (Yang et al. 2013). ID3 has also been shown to play a 
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complex role with atherosclerosis. ID3 expression is increased by hyperlipidemia 
and oxidized LDL (Taylor et al. 2006). ID3 regulates angiotensin II and carotid 
intima-media thickness. Angiotensin II promotes hyperplasia through up-regulating 
ID3 (Owens. 2009). The ID3 SNP could be a potential loss of function mutation if 
it inhibits the functioning of E proteins, thus being an atheroprotective factor. As 
shown in Figure 1.2, ID3 may impact vascular cell dysfunction leading to intimal 
lesions. 
Figure 1.2 ID3 molecular mechanism & vascular diseases. Summary illustration of ID3 signaling involved 
in vascular disease pathogenesis. ID3 signaling can lead to neo-intimal lesions or vascular remodeling by 
transcriptional regulation of the target genes described above.  
 
 ID3 stimulates visceral adipose VEGFA expression, depot expansion and 
micro-vascular blood volume (Cutchins et al. 2012). ID3 promotes angiogenesis in 
HFD (high-fat diet)-induced visceral adiposity (Cutchins et al. 2012). ID3 KO shows 
a protective effect from HFD-induced visceral fat depot expansion. Furthermore, 
HFD-induced VEGFA expression in visceral adipose tissue was completely 
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abolished by loss of ID3. BMP9 induces both ID1 and ID3 which are necessary for 
induction of EphrinB2 (Kim et al. 2012). A summary in Figure 1.3 shows an ID3 
signaling pathway involved in vascular malformations.  
Figure 1.3 ID3 involvement in arteriovenous malformation. Summary of experimental studies showing 
impact of ID3 in vascular cell dysfunction. 
 
Neurological Disorders. The ID3 gene is biologically relevant to neurological and 
behavior research because of its involvement in the stress response, neural 
plasticity, and neural circuitry. Molecular genetic studies in mice have shown that 
ID3 is required for embryonic neurovascular development. Genetic loss of ID1 and 
ID3 led to deviant neurovascular formations resulting in death (Lyden et al. 1999). 
ID1 and ID3 mutants showed premature differentiation of CNS radial glial cells that 
greatly increased neurons. Since radial glial cells, function as scaffolds for 
developing blood vessels in the CNS, alterations to their development in ID1/ID3 
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knockout mice may contribute to deviant blood vessel morphogenesis and 
hemorrhage. ID1 and ID3 may function beyond maturation of the CNS 
neurovasculature because other pathways such as Notch1 activation do not 
support neurovascular disorders (O’Brien et al. 2012; Solozobova et al. 2012).  
Psychopathologies such as anxiety and depression have been associated with ID3 
methylation status. Epigenetic changes in ID3 have been associated with 
maltreatment of children as well as demonstrated as a predictor for depression.  
Montalvo-Ortiz et al reported epigenetic alterations in DNA derived from saliva in 
three genes predicted depression in a cohort of maltreated children: ID3, 
Glutamate NMDA Receptor (GRIN1), and Tubulin Polymerization Promoting 
Protein (TPPP) (Montalvo-Ortiz et al. 2016). Studies of the expression of these 
genes from medial prefrontal cortex (mPFC) tissue of mice subjected to a model 
of maternal neglect, which comprised of maternal separation and early weaning 
(MSEW). Behavioral tests were performed in MSEW and control adult male mice 
by the higher plus maze (EPM) and forced swimming test (FST), respectively 
(Montalvo-Ortiz et al. 2016). Behavioral differences in the EPM and FST tests 
showed that these genes ID3, GRIN1 and TPPP gene could predict anxiety and 
depression. Based on these studies, ID3 may contribute to the etiology of anxiety 
and depressive phenotypes when exposed to early life stress (Montalvo-Ortiz et 
al. 2016) (Figure 1.4).  
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Figure 1.4 Epigenetic mechanism of ID3 in neurological disorders. Summary of ID3 involvement in 
neurological disorders is presented. 
Both environmental & genetic factors contribute to the progression of MetS 
and neurodegenerative disorders (Campos-Peña et al. 2017). Numerous studies 
have demonstrated that pre-diabetes and diabetes mellitus support cognitive 
decline related to Alzheimer's disease (AD) and vascular dementia (Campos-Peña 
et al. 2017). For example, sucrose-treated mice develop mitochondrial 
abnormalities with significant increase in Aβ levels, and slight increase in pTau 
levels which links metabolic perturbations from sucrose consumption with the AD-
like pathology. Epigenetic changes in ID3 have been associated with maltreatment 
of children as well as demonstrated as a predictor for depression (Weder et al. 
2014). Another epigenetic study of individuals with Autism spectrum disorders 
(ASD) revealed a significant association with a microRNA that targets ID3 
(Sarachana et al. 2010). This is interesting as ID3 is also a neuronal target of 
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MeCP2 which is the causative gene for Rett syndrome in which afflicted children 
often exhibit autistic-like behaviors (Peddada et al. 2006). The overlap in the 
clinical symptoms of ASD, ADHD, and neurodegenerative disorders raises the 
question of whether epigenetic regulation of ID3 plays a role.  
Population-based studies have demonstrated an association between toxic 
environmental chemical exposures and impaired neurodevelopment that may  
impact neurobehavioral disorders (Rossignol et al. 2014). Exposure to air 
pollutants from traffic and coal emissions are well-known risk factors for both 
attention deficit hyperactivity disorder (ADHD) and autism spectrum disorders 
(ASD) (Heilbrun et al. 2015). Polychlorinated biphenyls (PCBs) are endocrine-
disrupting chemicals shown to adversely affect cognitive performance. Children 
exposed to PCBs have shown behavioral impairments as well as significant deficits 
in verbal and full-scale IQ (Chen et al. 1994). Urban areas are important regional 
sources of airborne PCBs and population-scale airborne exposure. Although PCBs 
have not been intentionally produced in the U.S. since the late 1970s, they 
continue to be detected in ambient air samples throughout the world (NIEHS, NIH). 
PCBs are measurable in the blood of nearly 80% of Americans over age 50 years 
(Shanahan et al. 2015). Hence, exposure to PCBs has been proposed to disrupt 
developing neuronal circuits that may cause developmental brain disorders such 
as learning disorders (LD), ADHD, and autism.  
Endothelial cells of the blood-brain barrier (BBB) may provide clues in the 
study of brain health, behavior, and the environment (He et al. 2014). Inhaled air 
pollutants can disrupt the BBB by inducing pro-inflammatory cytokines that act on 
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endothelial cells (Genc et al. 2012). We have shown evidence for how PCB-
induced reactive oxygen species (ROS) may contribute to cerebral vascular 
phenotype changes with the goal of understanding consequences of 
environmental exposures have on the BBB (Das and Felty. 2015). Toxic chemical 
exposures can change brain gene expression through regulatory epigenetic 
mechanisms involving alterations in DNA methylation and histone acetylation. 
Evidence from animal studies show that epigenetic programming by fetal exposure 
to toxicants has long-lasting consequences for gene expression in the brain as well 
as behavior (Kundakovic et al. 2015). Epigenetic changes in ID3 have been 
associated with maltreatment of children as well as demonstrated as a predictor 
for depression (Weder et al. 2014). Epigenetic biomarkers in peripheral tissues 
(blood, saliva, or buccal cells) may be useful to predict neurodevelopmental 
disorders in humans. Exposures to prenatal stress, famine, and pollution/toxins, 
factors known to affect brain development, have been associated with epigenetic 
variation in human peripheral tissues (Perera et al. 2011). Based on these 
evidences, we postulate that ID3 can be a useful biological marker of epigenetic 
perturbations caused by toxic chemical exposure in children/adolescents (Figure 
1.5). 
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Figure 1.5 ID3 signaling pathway proposed in development of Autism Spectrum Disorder. Summary of 
ID3 involvement shows regulation of various genes causing changes in various processes such as modulation 
of synapses, circadian rhythm signaling, and collagen formation/stability.  
 
Kidney disease. Lipoprotein abnormalities have been reportedly linked to renal 
dysfunction in chronic kidney disease patients. Nackiewicz et al reviewed the 
prominent characteristics of kidney disease previously stated in ApoE-/-ID3-/- 
double knockout mice; and show that ID3 in hyperlipidemic mice directly effects 
vulnerability to kidney disease. ID3 deficiency may intensify CXCL1 production by 
glomerular cells in response to inflammatory lipids and the resulting macrophage 
recruitment. Because ID3 is present in multiple cell types, it is also conceivable 
that other glomerular cells lacking ID3 may contribute to cytokine production in vivo 
(Tenger and Zhou. 2003). Therefore, the reno-protective effect of ID3 may be 
through regulation of local chemokine production. ID3 is known to directly interact 
with more than 30 different transcription factors (Lynn et al. 2010). Noticeably, a 
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change in the ID3 function may impact a wide range of protein-protein interactions 
with potentially significant consequences (Nackiewicz et al. 2014). In dissimilarity 
to the findings of Nachkiewicz et al, in ApoE-/-ID3-/- mice with glomerulonephritis, 
the hyperlipidemic ID3-/- mice did not express meaningful increase in glomerular 
immune complex deposition associated to hyperlipidemic WT mice. Apoliprotein E 
deficiency is known to cause enlarged immune responsiveness (Zhao et al. 2016) 
and these results add significance to the study in dissecting the effects of ID3 alone 
on kidney disease.  
Clinical studies deliver indication for the relationship between lipids and 
chronic kidney disease. Nevertheless, they fail to elucidate why certain individuals 
(in the absence of diabetes or MetS) are probable to develop chronic kidney  
disease (Liu et al. 2012). Increased susceptibility to atherosclerosis has been 
reported to be associated with an ID3 single nucleotide polymorphism (SNP) 
(Doran et al. 2010). The overall preliminary findings in humans suggest a 
significant association between the same ID3 SNP and proteinuria, specifically 
influenced by small low density lipoproteins (p=0.0024) (Tenger and Zhou. 2003). 
C57BL/6 male mice on high fat diets (60% calorie from fat) develop MetS 
connected with obesity, elevated plasma glucose, proteinuria and 
glomerulonephritis (GN) and this may be due to decrease in renal AMP activated 
protein kinase, a cellular energy sensor (Declèves et al. 2011). However, C57BL/6 
female mice on high fat diets develop GN and proteinuria only in the absence of 
ID3 suggesting distinct pathogenic mechanisms between females and males. 
Examining molecular mechanisms in mice has recognized ID3 as a unique 
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transcription factor that may contribute to kidney disease and provide mechanistic 
links between atherosclerosis, hyperlipidemia, and kidney disease in humans. A  
summary of ID3 pathway contributing to chronic kidney disease is shown in Figure 
1.6. 
 
Figure 1.6 ID3 involvement in kidney disease. Summary illustration shows a link to hyperlipidemia and 
atherosclerosis. 
 
Cancer. Deregulation of ID genes are reported in in human cancers such as non-
small cell lung cancer (NSCLC) and colon cancer. ID3 contributes in generation of 
hematopoietic stem and progenitor cells (HSPC) associated with 
myeloproliferative disease (MPD) (Keller, NCI Division of Basic Sciences). ID1 and 
ID3 associated with the tumor promotion and metastasis (Castanon. 2013). Poor 
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response to chemo-radiotherapy have been reported in NSCLC patients with 
elevated ID1 and ID3 protein expression (Castanon et al. 2013). Regulation of p21 
by ID1 and ID3 has been seen as the vital mechanism inhibiting the accumulation 
of additional DNA damage and subsequent functional low energy of colon-initiating 
cells (CC-ICs). Genetic silencing of ID1 and ID3 increases chemotherapy 
sensitivity in CC-ICs suggesting that these molecules allow cancer cells to be drug 
resistant (O’Brien et al. 2012). Summary illustration of ID3 signaling involved in 
various cancer pathways is shown in Figure 1.7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 ID3 involvement in various types of cancer. Summary of ID3 signaling pathways involved in 
Colon and Lung Cancer (Left panel). ID3 contribution to tumor angiogenesis in brain cancer (Right panel). 
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Glioblastoma multiforme (GBM) tumors contain glioma stem cells or GSCs which 
are an implicated for glioma resistance to treatment (Bao et al. 2006; Nakano and 
Kornblum. 2006; Chalmers. 2007; Esposito et al. 2012; Phi et al. 2013). ID3 is also 
shown to be connected with medullobastoma in children (Phi et al. 2013). Inhibition 
of ID3 reduced proliferation, migration, and increased apoptosis of 
medullobastoma cells. Potential molecular mechanisms of ID3 in brain cancer are 
shown in Figure 1.8. 
 
Figure 1.8 ID3 and brain cancer mechanisms. Signaling pathways of ID3 involved in brain cancer are 
summarized in the illustration. 
 
Bone Disease. Osteogenesis imperfecta (OI) is a condition of fragile or brittle 
bones that break easily. OI affects 1 in 15,000 live births resulting in recurrent 
fractures and reduced mobility, with significant influence on quality of life 
(Balasubramanian et al. 2016). BMPs (bone morphogenetic proteins) are 
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morphogenetic signaling molecules vital for embryonic modelling. To find 
molecular understanding into the effect of BMPs on morphogenesis, Hollnagel et 
al examined novel genes directly activated by BMP signaling. CDM (chemically 
distinct growth medium)-cultured ES cells reacted very stringently to stimulation by 
numerous activin A, mesoderm inducers (BMP2/4), as well as fibroblast growth 
factor (Hollnagel et al. 1999). Using cDNA cloning, six BMP target genes were 
recognized. These include ID3, which exhibited convincing mRNA initiation, and 
the relatively stimulated Cyr61, DEK, and eIF4AII genes, as well as a gene 
translating a GC-binding protein. Alongside ID1, ID2, and ID3 genes were initiated 
by BMP4 in both ES cells and arrangement of various cell lines. ID genes encode 
negative regulators of basic helix-loop-helix transcription factors. In vivo, ectopic 
expression was observed of ID3 and Msx-2 mRNAs in Ft/1 embryos at intersecting 
regions of ectopic Bmp4 misexpression. As a result, Hollnagel et al proposed that 
the target genes of BMP4 signaling demonstrated here are part of BMP-stimulated 
initial processes of mammalian development. The expression arrangements of 
Msx-1, Msx-2, c-jun, ID1, ID2, and ID3 in normal mice versus those lacking in 
BMP2, BMP4, and BMP2/4-type I receptor will be of distinctive interest to compare. 
The promoters of the genes recognized in the analysis will aid as valuable tools to 
illustrate the molecular governing circuits that are overseen by BMP signaling 
(Hollnagel et al. 1999). 
 ID proteins, including ID1, ID2, and ID3, are involved with essential 
binding factor α-1 (Cbfa1) to trigger debilitated transcription of the osteocalcin 
(OCL) and alkaline phosphatase (ALP) gene, commanding to weakened ALP 
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action and osteocalcin (OCL) production. ID acts by hindering the specific-
sequence binding of Cbfa1 to DNA and diminishing the expression of Cbfa1 in cells 
experiencing osteogenic differentiation (Luan et al. 2008). Summary illustration of 
ID3 signaling in OI or brittle bone disease shown in Figure 6. p204, an interferon-
inducible protein that acts with both Cbfa1 and ID2, debilitated the ID2-mediated 
inhibition of Cbfa1-induced ALP action and OCL production. Luan et al establish 
that p204 interrupted the binding of ID2 to Cbfa1 and facilitated Cbfa1to bind to the 
promoters of its target genes. Furthermore p204 stimulated the translocation from 
nucleus to the cytoplasm and enhanced the degradation of ID2 by ubiquitin–
proteasome pathway during osteogenesis. Nucleus export signal (NES) of p204 is 
necessary for the p204-enhanced cytoplasmic translocation and degradation of 
ID2, since a p204 mutant-requiring NES lost these activities. Taken together, ID 
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proteins help to shape a regulatory circuit and take part to control osteoblast 
differentiation (Luan et al. 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 ID3 involvement in brittle bone disease pathogenesis. ID3 regulates various genes leading to 
osteoblast differentiation, which can contribute to osteogenesis imperfecta as described in the summary 
illustration. 
 
  ID1 and ID3 function to regulate bone metabolism in vivo (Maeda et al. 
2004). ID1/ID3 heterozygous knock out mice, showed that the thickness of 
calvarial junctions was attenuated by more than 50% (Maeda et al. 2004). 
Suppression of proliferation and mineralization in osteoblasts resultant from 
ID1/ID3 heterozygous knock out mice was proposed as a mechanism. Moreover, 
ID1/ID3 heterozygous knock out mice inhibited BMP-stimulated bone development 
in-vivo. Hence, ID1 and ID3 are critical regulators that support bone formation in 
vivo (Maeda et al. 2004).  
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 The connection between mechanisms of MetS and bone mineral density 
(BMD) is controversial (Muhlen et al. 2007). Muhlen et al examined the association 
of MetS with osteoporosis, osteoporotic fractures, and BMD. MetS was associated 
with decreased, not increased BMD. Frequency of osteoporotic non-vertebral 
breakages was greater in members with MetS. MetS may be an additional risk 
factor for osteoporotic fractures (Muhlen et al. 2007). Occurrence of MetS at 
reference was 23.5% in men and 18.2% in women. Age-adjusted analyses 
demonstrated in both men and women with MetS had increased BMD at total hip 
when compared to those without MetS (p<0.001 and p=0.01, respectively). Men 
not women with MetS furthermore had greater BMD at femoral neck (p=0.05). 
Subsequently modifying for BMI, these connections were inverted, such that MetS 
was linked with decreased and not increased BMD. Occurrence of osteoporotic 
non-vertebral breakages was increased in participants with MetS. The connection 
of MetS with increased BMD was explained by the increased BMI in those with 
MetS (Muhlen et al. 2007). 
 
Autoimmune Diseases. MetS has been involved in autoimmune diseases. One 
particular autoimmune disease is Primary Sjögren’s syndrome (pSS), which is 
primarily categorized by inflammatory association of the exocrine glands important 
to dry eye and mouth. Numerous organ systems can be disturbed which can cause 
a wide variety of extra-glandular indicators, such as small airway disorders, 
multiple sclerosis-like disease, peripheral neuropathy glomerulonephritis, and 
lymphoma (Maeda et al. 2004). pSS predominately affects females (9:1), with a 
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frequency in the overall population from 0.1 to 0.6 %. Studies evaluating patients 
with rheumatoid arthritis (RA) (Sakurai et al. 2004) and systemic lupus 
erythematosus (SLE) (Sinicato et al. 2013) have shown that inflammation plays a 
role in the progression of hypertension, diabetes mellitus, and MetS (Pereira et al. 
2009).  
 The ID3 gene is involved in the growth and function of B and T cells. 
Deficient ID3 mice develop autoimmune disease comparable to human Sjögren’s 
syndrome (pSS). Together B and T lymphocytes have been involved to contribute 
to the disease phenotype in this model (Guo et al. 2011). The up-regulation of ID1 
and ID3 genes has been reported in patients with rheumatoid arthritis (RA) 
(Sakurai et al. 2001). Elevated expression of ID1 and ID3 in endothelial cells has 
been proposed to contribute to severe angiogenesis found in RA. 
 
Conclusion 
 We have comprehensively reviewed the existing evidence to illustrate the 
association between ID3 and metabolic perturbations. Furthermore, we extended 
this understanding of how ID3 and metabolic perturbations by environmental 
factors such as EDCs can modify chronic disease risk and health outcomes. ID3 
has been seen to interact with multiple diseases such as cancer, vascular, 
neurological, autoimmune, & bone. Epidemiological and animal model studies 
have shown connections between ID3 and metabolic perturbations in chronic 
disease. Research is warranted to better define the influence of EDCs to ID3-
induced metabolic perturbations. This may lead to novel pathways for how the 
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interaction of ID3, EDCs, and metabolic disorders exacerbate complex chronic 
disease; and can help public health professionals control these metabolic 
disorders. 
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CHAPTER III 
MANUSCRIPT 2 
Association of PCB exposure in Peripheral Arterial Disease (PAD) Among the U.S. 
Population: NHANES 1999-2004  
Background. Peripheral arterial disease (PAD) is a subclinical hallmark of 
coronary artery disease and identifies asymptomatic individuals at high risk for 
cardiovascular disease events.  Current reports have shown association with a 
number of chemicals suspected to act as endocrine disruptors (EDs) by emulating 
synthetic or natural estrogen resultant in an increase in disease risk such as 
cancer, cardiovascular & vascular, and neuro-degenerative disorders. 
Polychlorinated biphenyls (PCBs) have been recognized as an endocrine disruptor 
due to their capability to affect & interfere with reproductive function and 
development in animals and humans by increasing estrogen activity or blocking 
estrogen action. Recent animal studies have suggested that PCB exposure may 
have a role in several mechanisms involved in the development of CVD including 
oxidative stress, vascular & endothelial dysfunction, weight gain, and insulin 
resistance. We conducted an Environmental-Wide Association Study (EWAS), in 
which epidemiological data are systematically and compressively interpreted in a 
method corresponding to a Genome Wide Association Study (GWAS). 
Objectives. The purpose of this study is to examine association between exposure 
to PCBs & peripheral arterial disease (PAD) in a nationally represented sample of 
the U.S. population.   
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Methods. We utilized participants in the National Health and Nutritional 
Examination Survey (NHANES) 1999–2004. We estimated associations between 
exposure to polychlorinated biphenyls (PCBs) and PAD (ankle–brachial index < 
0.9) using complex survey and logistic regression models adjusted for potential 
confounders. 
Results. Analysis demonstrated higher geometric levels of all 6 PCB congeners 
in both PAD diagnosed participants and defined AS participants when compared 
to the rest of the population. Furthermore PCB153 was shown to have the highest 
geometric mean amongst all PCB congeners in both participants diagnosed with 
PAD (53.38 ng/g) and AS defined participants (38.66 ng/g). Furthermore adjusted 
models for PAD confounders (diabetes, smoking, & alcohol use), with gender, age, 
and race showed significant association with higher exposure of PCBs and 
increased risk of PAD and AS. 
Conclusion. Our results suggest an association between environmental exposure 
to polychlorinated biphenyls (PCBs) & increased risk of peripheral arterial disease 
(PAD) and atherosclerosis (AS) among the U.S. population. Although the use of 
PCBs have been discontinued, exposure via the environment still remains to pose 
threats on the general population’s health.  
Key words: ankle–brachial index, endocrine disrupting chemicals, NHANES, 
peripheral arterial disease, polychlorinated biphenyls, vascular disease 
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Introduction 
Humans are exposed to a variety of environmental exposures and these 
exposures may interact with one another to modify health risk outcomes. The 
cardiovascular system is a significant target of these environmental exposures via 
genomic and non-genomic pathways (Chambliss et al., 2002). The estrogen 
receptor (ERα/β) has been shown in endothelial cells, human coronary arteries, 
and cardiomyocytes (Kim-Schulze et al., 1996; Yang et al., 2004). Peripheral 
arterial disease (PAD) can lead to lasting disability but general diagnosis of the 
disease frequently appears late in the process. The first nationally representative 
community survey done in the U.S. sponsored by the PAD coalition established 
75% of respondents were unaware PAD existed and the remaining 25% knew 
minimal correct information (Hirsch et al., 2007). Previous studies reported an 
association between Bisphenol A (BPA), an endocrine disrupting chemical 
produced in very large volume (>2 million metric tons manufactured globally in 
2003) and used in the creation of polycarbonate plastics and containers used for 
food and beverages (Vandenberg et al., 2009). Nevertheless, the association of 
other endocrine disrupting chemicals with cardiovascular disease risk has never 
been without debate.  
One particular compound that has been known to show estrogenic-like 
attributes are polychlorinated biphenyls (PCBs). We previously demonstrated that 
planar and co-planar PCBs induce the expression of different genes compared to 
estradiol. Furthermore PCBs can promote vascular lesion formation by activating 
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gene networks involved in endothelial cell adhesion, cell growth, and pro-
inflammatory molecules which were dissimilar from natural estrogen. (Felty et al., 
2010). Peripheral arterial disease (PAD) is a subclinical measure of atherosclerotic 
vascular disease (Newman et al. 1993) that is an independent predictor of 
following CVD incidence (Murabito et al. 2003; Newman et al. 1993). Criqui et al. 
(1992) reported that individuals among originally free of CVD, an ankle–brachial 
index (ABI) of < 0.9 was associated with a hazard ratio of 6.6 for future risk of death 
from coronary heart disease even after adjusting for cardiovascular risk factors 
including age, sex, body mass index (BMI), smoking, and high cholesterol levels. 
Guidelines (American Diabetes Association 2003; Hirsch et al. 2006) exist for 
defining PAD based on the ABI, which can be measured even in large population-
based studies (Selvin and Erlinger 2004).  
In this study, we examined the independent association between 6 
individual PCBs, the sum of non-dioxin-like PCBs, and the sum of dioxin-like-PCBs 
with diagnosis of peripheral arterial disease and participants defined with 
atherosclerosis in the NHANES (National Health and Nutrition Examination 
Survey) in three year cycles: 1999 – 2000, 2001 – 2002, and 2003 – 2004.  The 
aim of this study is to asses: 1) the mean PCB levels in PAD defined participants 
and atherosclerosis compared to non-diagnosed participants; and 2) the 
association between higher PCB exposure and increased risk of PAD/AS.  
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Methods 
Study design and population. The current study is based on data from NHANES 
1999-2004. NHANES survey includes a stratified multistage probability sample 
representative of the civilian non-institutionalized U.S. population. Selection was 
based on counties, blocks, households, and individuals within households and 
included the oversampling of non-Hispanic blacks and Mexican Americans in order 
to provide stable estimates of these groups. Participants provided written informed 
consent before their participation. Furthermore approval was obtained from the 
Human Subjects Committee in the U.S. Department of Health and Human 
Services. Measurements of ABI, a subclinical measure of atherosclerosis (Criqui 
et al. 1992; Newman et al. 1993), were obtained for the subsample of participants 
≥ 40 years of age. The current study sample consisted of participants ≥ 40 years 
of age among whom polychlorinated biphenyls was available. This resulted in 
participants (461), of whom had PAD and participants (390) whom were indicated 
as having atherosclerosis. Subjects who were excluded because of missing 
covariates were in general similar to the NHANES cohort in terms of age, sex, 
race/ethnicity, and education (data not shown). Secondary analysis of the 
nationally collected data was done using variables of interest, which were only 
measured concurrently during the three NHANES cycles from 1999-2000, 2001-
2002, and 2003-2004. NHANES uses a multifaceted sampling design (multistage, 
probability, cluster and stratified) for continuous collection and release of 2-year 
cross-sectional data sets. Approval for these questionnaires, age, appropriate 
examinations and laboratory testing were given to NHANES by the CDC/ATSDR 
 57 
 
institutional review board of the CDC. The current study was considered exempt 
from review by the local institutional review board.  
Peripheral Arterial Disease (PAD) identification. The NHANES ABI is routinely 
calculated by their computer system and verified by the National Center for Health 
Statistics before data release. Systolic pressure is measured on the right arm 
(brachial artery) and both ankles (posterior tibial arteries). If the participant has a 
rash or open wound on the right arm, dialysis shunt, right-sided radical mastectomy 
or any additional condition that would interfere with accurate measurement or 
cause discomfort to the participant, the left arm is used for the brachial pressure 
measurement. Systolic blood pressure is measured twice at each site for 
participants aged 40-59 years and once at each site for participants aged 60 years 
and older. If a health technician is unable to acquire a reading at a site they may 
attempt an additional reading at the same site after a short-term resting period. 
The right ABPI was obtained by dividing the mean systolic blood pressure in the 
right ankle by the mean blood pressure in the arm. The left ABPI was obtained by 
dividing the mean systolic blood pressure in the left ankle by the mean blood 
pressure in the arm. The mean blood pressure value for the arm and ankles are 
computed based on the first and second reading at each site. Since the second 
reading for all participants 60+ years of age is missing the mean values are in fact 
the first recorded blood pressure reading at a site. This may also be true for 40-59 
year old participants who have a missing value for the first or second blood 
pressure reading. Individuals are excluded from the exam if they have bilateral 
amputations or weigh over 400 pounds (due to equipment limitations). In addition 
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to these exclusion criteria, some participants who were eligible for the exam (40 
years of age and older) might not have received the exam due to various reasons: 
1) casts, ulcers, dressings, or other conditions of the participant interfered with 
testing, 2) participant could not understand the test instructions, 3) participant 
became ill and the test could not be performed, 4) there was an equipment failure, 
5) participant refused, 6) participant came late or left early from the MEC and the 
LED exam could not be performed, or 7) some other reason. As a result, these 
eligible individuals will have missing data for the ABPI variables. PAD was defined 
as an ABI <0.7. Values 0.9 < ABI < 1.3 were considered normal. Measurements 
0.7 < ABI < 0.9 were defined as indication of atherosclerosis as seen in Table 2.1. 
ABI Value Reading Interpretation 
ABI < 0.7 Peripheral Arterial Disease (PAD)  
0.7 < ABI 
<0.9 Atherosclerosis (AS) 
0.9 < ABI < 
1.3  Normal  
                                 Table 2.1 ABI (Ankle-Brachial Index)  
Polychlorinated Biphenyl (PCBs) measurements. Individual PCB congeners 
were measured through blood serum concentration in a demonstrative, random 
one-third subsample of people 12 years of age older in three survey cycles: 1999 
- 2000, 2001 – 2002, and 2003 – 2004. Each survey cycle sampled for various 
PCB congeners. NHANES sampled for 22 PCB congeners in the 1999 – 2000 
survey, 34 PCBs congeners in the 2001-2002 cycle, and 38 PCB congeners in the 
2003-2004 cycle. PCB congeners were measured in blood serum by high-
resolution gas chromatography/isotope-dilution high-resolution mass spectrometry 
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(HRGS/ID-HRMS). Both wet-weight and lipid adjusted values for each sample, 
corrected for sample weight and analyte recovery was provided by NHANES. 
However we used lipid adjusted values in our analysis. Results for PCBs are 
reported on a whole weight (ng/g or ppb) and a lipid-adjusted basis (ng/g or ppb). 
Laboratory methods were consistent between survey cycles and are fully available 
online (CDC 2013b). A detection limit variable (LOD) is specified for all PCB 
congeners in the dataset. The variable LOD has two numerical values: “1” 
designates that the results was below the limit of detection and “2” designates that 
the results was equal to or above the limit of detection. To account for bias with 
PCBs below the LOD, we selected 6 individual PCB congeners that were 
represented & available from 1999 – 2004 and had concentrations above the LOD 
in at least 60% of the study subjects. The overall analysis explored the association 
between peripheral arterial disease variables in the U.S. population using the 
following 6 PCB congeners: 2,2’,3,4,4,5,5’-heptachlorobiphenyl (PCB180), 
2,2’,4,4’,5,5’-hexachlorobiphenyl (PCB153), 2,2’,3,4,4’,5-hexachlorobiphenyl 
(PCB138),  2,3’,4,4’,5- pentachlorobiphenyl (PCB118), 2,2’4,4’,5- 
pentachlorobiphenyl (PCB99), and 2,4,4’,5 tetrachlorobiphenyl (PCB74). We also 
conducted analysis on the sum of dioxin-like PCBs (074 and 118) and non-dioxin-
like PCBs (099, 138,153,180).  
Covariates. We considered a variety of potential confounders based on well-
established risk factors for peripheral arterial disease and review of the literature. 
The resulting potential confounders were either taken as a laboratory 
measurement or self-reported in the questionnaire interviews. The demographic 
 60 
 
variables of gender (male/female), race (Mexican American, Other Hispanic, Non-
Hispanic White, Non-Hispanic Black, and other race) and age (≥40-59, 60-74, and 
≥ 75) were obtained during the NHANES home interview (CDC, 2012). Others 
obtained include: smoking, alcohol use (yes/no), BMI (18.5 to < 25, 25 to <30, ≥ 
30), diabetes (yes/no), estradiol levels, sex hormone binding globulin, 
testosterone, education, and annual income. 
Statistical Analysis. All statistical analysis were performed using SAS 9.4 (SAS 
Institute Inc., Cary, NC, USA). These analyses used 5% significance level (p≤ 
0.05). We used logistic regression models to calculate odds ratios (ORs) and their 
95% CI (confidence intervals) to investigate the risk between PCBs and peripheral 
arterial disease. According to the National Center for Health Statistics guides a six 
year subsample weight was calculated to adjust for oversampling of minority 
groups in the merged 1999-2004 NHANES data cycles (CDC 2013b). Non-missing 
values for serum concentrations below the LOD were assigned a serum level of 
the LOD divided by the square root of two. In our analysis, all lipid adjusted serum 
PCB concentrations were log transformed to satisfy normality assumptions. 
Participants were categorized as the following methods depending on data 
analysis: < LOD vs. ≥ LOD; < LOD to 50th percentile vs. ≥ 50th percentile; and < 
LOD to 50th percentile vs. 50th percentile to 75th percentile vs. ≥ 75th percentile. 
We also conducted separate analyses on all participants with serum PCB levels > 
LOD where PAD & AS cases were compared with normal cases. Significance was 
set at p < 0.05 for all analyses. 
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We utilized survey means analysis (PROC SURVEYMEANS) to account for 
the complex sampling design of NHANES and to obtain weighted means, 95% 
confidence intervals, and standard errors of individual PCBs, the sum of dioxin-like 
PCBs, and the sum of non-dioxin-like PCBs. A two-sided student t-test was 
calculated using PROC SURVEYREG to test if the mean PCB levels between 
participants who were identified with PAD, AS, and normal participants were 
significantly different. Geometric mean (GM) PCB levels and geometric standard 
errors (GSE) were reported for peripheral arterial disease (PAD) status, 
atherosclerosis (AS) status, age at interview, and race/ethnicity for all participants 
with individual serum PCB levels. Computational mean serum levels of dioxin-like 
and non-dioxin-like PCBs and 95% CIs were reported for PAD status and select 
confounding variables. Age was divided into three groups (≥ 40-59 years, 60-74 
years, and ≥ 75 years) that were selected based on the age distribution of PAD 
cases, AS cases, and normal cases in the population. Race/ethnicity was divided 
into five groups (Mexican American, other Hispanic, Non-Hispanic White, Non-
Hispanic Black, and other race). We furthermore calculated both crude and age 
standardized GMs for PAD cases and non-cases in the population with PCB levels 
above the LOD. We used the direct technique for age adjustment provided by the 
CDC (CDC 2014). 
Results 
Descriptive Statistics. The study population includes 6,624 participants ≥ 40 
years of age. Among the 6,624 participants, 461 (6.96%) were defined with PAD, 
390 (5.89%) for atherosclerosis (AS), & 5773 (87.15%) were defined as normal 
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(Table 2.2). Participants were equally distributed among gender: males – 3,489 
(49.77%) to females – 3,135 (50.23%). The majority of the participants in each of 
the categories were predominantly Non-Hispanic White: 268 (3.72%), 236 
(4.90%), and 3125 (69.64%) respectively. Participants in age group 60-74 years 
old were over-represented with defined PAD (199) and ≥ 40-59 years old with 
atherosclerosis (180). When asked if PAD identified participants ever smoked 72 
(1.84%) said “yes,” 10 (0.24%) said “sometimes,” and 150 (3.68%) said “no.”  
Various hormone levels were also assessed.  Estradiol levels between 5 -95 pg/mL 
were overrepresented 21 (3.18%) for participants with PAD; 31 (9.20%) for 
participants defined with AS; and 323 (85.44%) for normal participants.  For sex 
hormone binding globulin (nmol/L) ranges from 0.350 – 90 nmol/L were most 
represented by the population: 20 (2.88%) for PAD identified participants; 31 
(9.31%) for participants with AS; and 306 (82.69%) normal participants. Lastly 
testosterone levels (ng/mL) were also assessed for the population.  Measurement 
range from 0.020 – 9 ng/mL were overrepresented. Participants with PAD 
represented 22 (3.24%) participants; AS participants with 32 (9.36%); and 318 
(84.49%) for normal participants. 
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Table 2.2 Descriptive statistics for PAD & selected covariates among participants ≥ 40 years 
of age, NHANES 1999 – 2004.  
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Estimated percent distribution after applying NHANES sampling weights 
*ABI < 0.7 (PAD). 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal) 
  
Table 2.3 presents GMs and GSE of PCB concentrations (lipid-adjusted) 
by PAD status, AS status, and normal status. GM PCB levels were demonstrated 
as higher for all 6 PCB congeners for both participants defined with PAD as well 
as participants identified with AS when compared to the normal population (Table 
2.3). Overall GM levels of PCBs ranged from 13.47 ng/g (PCB074) being the 
lowest and 53.38 ng/g (PCB153) being the highest in participants with PAD. 
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Furthermore it was demonstrated that 6.19 ng/g (PCB099) and 38.66 ng/g 
(PCB153) were demonstrated as the lowest and highest GM levels in AS 
participants.   
 
Table 2.3 Geometric Mean PCB levels (ng/g) above the LOD by PAD status 
among participants ≥ 40 years of age, NHANES 1999-2004. 
 
1 Lipid Adjusted and log transformed polychlorinated biphenyls (ng/g) 
2 Geometric Means calculated after applying NHANES sampling weights 
*ABI < 0.7 (PAD). 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal) 
 
 
Figure 2.1 Geometric mean PCB levels (ng/g) by PAD status for participants ≥ 40 years of age, NHANES 
1999-2004.  
Geometric mean PCB levels were also examined by age group of 
participants (Table 2.4). The overall GM levels of PCBs increased significantly in 
Cases/Non-Cases Geometric Mean₂ (ng/g) (GSE)
Analyte₁ ABI < 0.7* 0.7 < ABI <0.9* 0.9 < ABI < 1.3* ABI < 0.7 0.7 < ABI <0.9 0.9 < ABI < 1.3 
PCB074 65 49 2871 13.47 (8.80, 20.61) 8.82 (7.15, 10.88) 7.82 (7.54, 8.11)
PCB099 57 76 3767 9.95 (7.078, 14.00) 6.19 (5.35, 7.16) 5.70 (5.53, 5.87)
PCB118 40 75 2866 15.02 (8.94, 25.24) 10.53 (8.20, 13.52) 8.90 (8.56, 9.26)
PCB138 58 76 3794 37.05 (28.04, 48.97) 25.18 (20.48, 30.96) 19.79 (19.11, 20.49)
PCB153 69 66 3803 53.38 (40.68, 70.04) 38.66 (30.64, 48.78) 27.68 (26.70, 28.70)
PCB180 62 72 3800 42.13 (33.00, 53.78) 31.11 (23.84, 40.60) 20.50 (19.71, 21.31)
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PAD participants as age group progressed except PCB099 which demonstrated a 
non-consistent trend (10.04 ng/g vs. 8.82 ng/g vs. 18.99 ng/g). In the first age 
group (≥ 40 – 59) GM levels of PCBs are demonstrated to be higher in PAD defined 
participants when compared to normal participant levels. Additionally the same 
trend is shown when comparing AS participants to the normal group.  In the second 
age group (60 – 74 years old), participants had higher GM PCB levels of congeners 
with the exception of PCB congener 180 that demonstrated lower GM PCB levels 
in normal participants when compared to PAD participants (Table 2.4). The 
population who were AS defined when compared to the normal population were 
shown as being higher. In the third age group (≥ 75 years old) all PCB congeners 
were shown to be higher in PAD identified participants when compared to normal 
participants. Furthermore higher PCB levels of participants whom were at defined 
AS participants were demonstrated with PCB congeners 74 and 118. Interestingly 
PCB 099, 138, 153, and 180 were shown to have higher PCB GM in normal 
participants when compared to AS participants.  
Table 2.4 Geometric Mean PCB levels (ng/g) above the LOD by peripheral arterial disease 
status by age groups, NHANES 1999-2004 
 
¹ Lipid Adjusted and log transformed polychlorinated biphenyls (ng/g);  
² Geometric Means calculated after applying NHANES sampling weights  
*ABI < 0.7 (PAD), 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal) 
Geometric Mean₂ (ng/g) (GSE, n)
Age: ≥ 40-59 Age: 60-74 Age: ≥ 75
ABI < 0.7* 0.7 < ABI <0.9* 0.9 < ABI < 1.3* ABI < 0.7 0.7 < ABI <0.9 0.9 < ABI < 1.3 ABI < 0.7 0.7 < ABI <0.9 0.9 < ABI < 1.3 
Analyte₁
PCB074 9.41 (2.59) 7.10 (0.73) 6.58 (0.14) 14.78 (0.50) 19.87 (2.53) 12.12 (4.02) 40.06 (5.46) 25.53 (5.54) 22.32 (1.05)
PCB099 10.04 (2.52) 5.54 (0.47) 5.14 (0.10) 8.82 (0.30) 8.69(1.11) 7.61 (2.53) 18.99 (3.13) 10.27 (2.97) 11.65 (0.52)
PCB118 9.01 (2.13) 8.48 (1.15) 7.56 (0.18) 17.42 (0.76) 22.96 (3.32) 13.18 (5.67) 54.77 (10.36) 50.02 (13.18) 24.40 (1.32)
PCB138 36.90 (9.13) 22.75 (2.54) 18.20 (0.39) 39.46 (1.20) 40.84 (4.63) 36.78 (7.43) 64.60 (8.86) 46.38 (11.75) 51.76 (2.06)
PCB153 52.80 (10.55) 35.51 (4.38) 25.61(0.57) 58.18 (1.59) 64.95 (8.62) 55.36 (10.15) 97.05 (12.95) 63.22 (10.94) 75.76 (2.71)
PCB180 38.98 (8.45) 28.80 (4.69) 18.91 (0.46) 48.13 (1.19) 50.25 (6.84) 49.84 (7.19) 65.00 (9.02) 44.38 (10.29) 60.77 (2.08)
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Figure 2.2.1 Geometric mean PCB levels (ng/g) by PAD status for participants ≥ 40-59 years of age, 
NHANES 1999-2004.  
 
Figure 2.2.2 Geometric mean PCB levels (ng/g) by PAD status for participants 60 - 74 years of age, 
NHANES 1999-2004. 
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Figure 2.2.3 Geometric mean PCB levels (ng/g) by PAD status for participants ≥ 75 years of age, 
NHANES 1999-2004.  
 
 
Table 2.5 presents age standardized GMs and GSEs of PCBs by 
race/ethnicity in participants with individual concentrations of PCBs above the 
LOD. Ethnic backgrounds that were demonstrated to have higher PCB 
concentrations when having PAD compared to normal participants include: 
“Mexican American,” “Non-Hispanic White,” “Other Race,” and “Non-Hispanic 
Black.” “Other Hispanic” demonstrated lower levels of PCB concentrations in PAD 
participants when compared to normal participants. Furthermore participants with 
AS in ethnic groups include: “Mexican American,” “Non-Hispanic White,” “Non-
Hispanic Black,” and “Other Race” demonstrated higher levels of PCBs when 
compared to normal participants. “Other Hispanic” AS participants showed lower 
PCB concentrations when compared to normal participants. 
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Table 2.5 Age standardized geometric mean PCB levels (ng/g) above the LOD by 
race/ethnicity among participants ≥ 40 years old PAD by age groups, NHANES 1999-2004. 
 
1 Lipid Adjusted and log transformed polychlorinated biphenyls (ng/g) 
2 Geometric Means calculated after applying NHANES sampling weight 
*ABI < 0.7 (PAD), 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal 
 
Table 2.6 demonstrates the computational means and 95% CIs of dioxin-
like serum levels of PCBs for PAD, atherosclerosis, normal, and selected 
covariates in the study population. Computational means of dioxin-like PCBs were 
higher in participants diagnosed with PAD (1.57 ng/g) compared to participants 
without PAD (1.35 ng/g). Furthermore PCBs were lower in participants with AS 
(1.33 ng/g) compared to normal participants. Mean dioxin-like PCBs increased with 
age in all three groups: PAD, AS, & normal participants. Other Hispanic was 
demonstrated to be the highest race diagnosed with PAD (1.68 ng/g) and Non-
Hispanic Black with AS (1.51 ng/g). Additionally all three age groups demonstrated 
a higher mean of PCB levels in both PAD participants & AS participants when 
compared to normal participants. 
Geometric Mean₂  (ng/g) (GSE, n)
Mexican American Other Hispanic
ABI < 0.7* 0.7 < ABI < 0.9* 0.9 < ABI < 1.3* ABI < 0.7 0.7 < ABI < 0.9 0.9 < ABI < 1.3 
Analyte₁ Analyte
PCB074 10.46 (6.56-16.69) 7.68 (5.50-10.72) 4.60 (4.29-4.93) PCB074 3.90 (3.87-4.01) 5.98 (2.20-16.22) 7.03(5.95-8.31)
PCB099 7.53 (4.97-11.43) 5.50 (4.28-7.08) 3.55 (3.35-3.77) PCB099 4.52 (4.10-4.35) 4.82 (2.65-8.77) 5.63 (5.00-6.35)
PCB118 10.83 (6.03-19.46) 10.05 (6.96-14.52) 5.71 (5.34-6.12) PCB118 3.54 (3.42-3.98) 6.85 (1.96-23.96) 9.81 (8.28-11.62)
PCB138 28.70 (17.25-47.72) 23.30 (17.39-31.21) 9.72 (9.02-10.47) PCB138 6.59 (6.43-8.42) 7.40 (1.84-29.80) 19.56 (16.64-22.98)
PCB153 36.97 (23.34-58.55) 37.56 (28.53-49.44) 12.57 (11.61-13.61) PCB153 7.97 (3.42-8.15) 8.33 (1.66-41.87) 26.36 (22.21-31.29)
PCB180 24.46 (14.99-39.90) 27.73 (19.04-40.41) 9.02 (8.25-9.87) PCB180 3.42 (3.14-3.88) 6.66 (2.01-22.04) 18.39 (15.48-21.85) 
Non-Hispanic White Non-Hispanic Black
ABI < 0.7 0.7 < ABI < 0.9 0.9 < ABI < 1.3 ABI < 0.7 0.7 < ABI < 0.9 0.9 < ABI < 1.3 
Analyte Analyte
PCB074 13.17 (7.67-22.61) 9.05 (7.14-11.48) 8.45 (8.08-8.84) PCB074 18.56 (10.53-32.70) 8.91 (6.61-12.00) 7.69 (7.07-8.36)
PCB099 9.53 (6.28-14.48) 6.27 (5.32-7.38) 5.75 (5.54-5.96) PCB099 14.15 (7.58-26.40) 7.53 (5.99-9.47) 7.40 (6.88-7.95)
PCB118 14.54 (7.42-28.53) 10.78 (8.13-14.30) 9.13 (8.70-9.59) PCB118 21.73 (12.04-39.20) 12.12 (7.94-18.51) 9.80 (8.87-10.82) 
PCB138 35.72 (25.63-49.80) 26.78 (21.74-32.99) 20.65 (19.80-21.55) PCB138 54.59 (32.07-92.93) 31.61 (14.00-71.36) 23.93 (22.01-26.02)
PCB153 52.22 (37.92-71.90) 41.52 (33.01-52.22) 29.32 (28.07-30.62) PCB153 78.34 (45.95-133.56 39.37 (15.94-97.22) 32.53 (29.82-35.49)
PCB180 42.66 (32.36-56.24) 33.69 (25.47-44.56) 22.27 (21.24-23.35) PCB180 54.35 (30.65-96.39) 38.61 (15.76-94.60) 21.91 (20.04-23.95)
Other Race
ABI < 0.7 0.7 < ABI < 0.9 0.9 < ABI < 1.3 
Analyte
PCB074 10.43 (10.22-11.23) 11.73 (11.70-11.88) 5.86 (5.02-6.85)
PCB099 5.77 (4.42-5.96) 8.02 (8.00-8.10) 5.64 (4.94-6.43)
PCB118 10.21 (10.15-10.45) 11.01 (11.00-11.02) 8.28 (6.89-9.94)
PCB138 21.21 (18.32-23.32) 21.70 (21.74-21.89) 19.01 (16.21-22.29)
PCB153 30.43 (29.23-31-75) 40.00 (40.0-40.2) 26.25 (22.15-31.11)
PCB180 24.42 (22.32-25.32) 26.20 (26.19-26.24) 18.28 (15.08-22.17)
 70 
 
Table 2.6 Serum levels of dioxin-like PCBs (ng/g) in the study population, participants ≥ 40 
years of age, NHANES 1999-2004. 
 
¹ Means calculated after applying NHANES sampling weights; lipid-adjusted and log transformed PCBs 
*ABI < 0.7 (PAD). 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal) 
 
Table 2.7 demonstrates the computational means and 95% CIs of non-
dioxin-like PCBs for diagnosis of PAD, AS, and normal population. Computational 
means was seen higher in diagnosed PAD participants exposed to non-dioxin-like 
PCBs compared to the normal population (2.18 ng/g vs.2.00 ng/g).  Interestingly, 
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means was seen lower in AS participants when compare to the normal population 
(1.95 ng/g vs. 2.00 ng/g). Additionally all individual races/ethnicities demonstrated 
higher non-dioxin-like PCB concentrations in PAD diagnosed participants when 
compared to the normal population. Individual races/ethnicities including: “Mexican 
American” and “Non-Hispanic Black” showed higher non-dioxin-like PCB exposure 
in participants with AS when compared to the normal population.  
Table 2.7 Serum levels of non-dioxin like PCBs (ng/g) in the study population, participants 
≥ 40 years of age, NHANES 1999-2004 
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¹ Means calculated after applying NHANES sampling weights; lipid-adjusted and log transformed PCBs 
*ABI < 0.7 (PAD). 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal) 
 
Geometric Means and 95% CI’s of PCB levels (lipid-adjusted) are reported 
in Table 2.8 for participants with PCB levels < LOD and ≥ LOD. All participants 
who reported concentrations of ≥ LOD who were diagnosed with PAD had higher 
GM levels of PCB congeners. Similarly, participants who reported concentrations 
of ≥ LOD who were AS participants had higher PCB congener levels (074, 099, 
158, and 180).  PCB congener 074 had higher GM in normal participants vs. ones 
who were AS participants (14.07 ng/g vs. 13.19 ng/g) and congener 118 
demonstrated comparable GM levels (11.51 ng/g vs. 11.32 ng/g) (Table 2.8)
 
 
 
 
 
 
 
 
2.8 Geometric Mean PCB levels (ng/g) by PAD status among participants ≥ 40 years of age, 
NHANES 1999-2004. 
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₁ Lipid adjusted and log transformed polychlorinated biphenyls (ng/g) 
₂ Geometric means calculated after applying NHANES sampling weights 
*ABI < 0.7 (PAD), 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal) 
 
We also adjusted the PCB levels into the following two groups < LOD to 50th 
percentile and ≥ 50th percentile (Table 2.9). Participants in the first group (< LOD 
to 50th percentile) with PAD showed higher GM PCB levels compared to 
participants who were defined as normal participants: PCB congener 074 (3.65 
ng/g vs. 3.10 ng/g); 099 (2.85 ng/g vs. 2.61 ng/g); 118 (3.82 ng/g vs. 3.60 ng/g). 
PCB congeners 138 (7.06 ng/g vs. 7.66 ng/g); 153 (6.51 ng/g vs. 9.59 ng/g); and 
180 (5.78 ng/g vs. 6.99 ng/g) showed higher levels of PCB GMs in normal 
participants then in participants defined with PAD. Furthermore a significant 
increase was seen in the second group (≥ 50th percentile) for PCB congener 074 
(17.68 vs. 11.20); 099 (13.06 vs. 8.03); 118 (28.26 vs. 14.09); 138 (45.30 vs. 
35.53); 153 (64.87 vs. 50.47) 180 (51.69 vs. 41.63). GM PCB concentrations 
between AS participants and normal participants were demonstrated to have little 
to no change between the two groups with the exception of PCB 153 (12.94 vs. 
Cases/Non-cases Geometric Mean₂ (ng/g) (95% CI)
ABI < 0.7* 0.7 < ABI <0.9* 0.9 < ABI < 1.3* ABI < 0.7 0.7 < ABI < 0.9 0.9 < ABI < 1.3 
Analyte₁
PCB074
< LOD 16 22 1467 4.27 (3.83-4.75) 4.12 (3.87-4.40) 3.71 (3.63-3.79)
≥  LOD 29 47 1382 25.70 (19.36-34.12) 13.186 (11.47-15.15) 14.07 (13.66-14.49)
PCB099
< LOD 11 13 1267 2.85 (2.44-3.34) 3.35 (3.16-3.54) 2.63(2.57-2.70)
≥  LOD 28 35 1322 21.21 (15.96-28.18) 10.06 (8.72-11.61) 12.29 (11.90-12.70)
PCB118
< LOD 3 3 574 2.39 (1.55-3.69) 3.63 (3.50-3.76) 2.94 (2.85-3.033)
≥  LOD 41 66 2250 18.28 (10.88-30.71) 11.51 (8.97-14.76) 11.32 (10.89-11.77)
PCB138
< LOD 0 0 78 N/A N/A 1.98 (1.89-2.07)
≥  LOD 58 76 3708 37.05 (28.03-48.97) 25.18 (20.48-30.96) 20.40 (19.72-21.10)
PCB153
< LOD 6 5 1080 4.07 (3.65-4.54) 4.99 (3.18-7.84) 5.58 (5.39-5.78)
≥  LOD 52 71 2530 62.71 (49.79-78.98) 44.28 (36.43-53.80) 40.82 (39.59-42.09)
PCB180
< LOD 0 0 217 N/A N/A 1.53 (1.39-1.69)
≥  LOD 58 76 3571 42.13 (33.00-53.78) 31.11 (23.84-40.60) 22.10 (21.28-22.93)
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9.59 for < LOD to 50%; 54.29 vs. 50.47 for ≥ 50%) and PCB 180 (44.85 vs. 41.63 
for ≥ 50%) (Table 2.9).  
Table 2.9 Geometric mean PCB levels (ng/g) by PAD status among participants ≥ 40 years 
of age, NHANES 1999-2004 
 
₁Lipid adjusted and log transformed polychlorinated biphenyls (ng/g) 
₂Geometric means calculated after applying NHANES sampling weights 
*ABI < 0.7 (PAD), 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal) 
 
We additionally divided lipid adjusted PCB GMs to three groups: < LOD to 
50%, 50% to 75%, and ≥ 75% (Table 2.10). Participants in groups <LOD to 50% 
demonstrated higher PCB concentrations in PAD defined participants when 
compared to normal participants (PCB congeners 074, 099, 118). PCB congeners 
138, 153, and 180 showed the reverse results and demonstrated higher PCB 
concentration levels in normal participants when compared to the participants 
defined with PAD. When comparing AS participants to normal, all PCB congeners 
were higher than PCB GM levels in normal participants for < LOD to 50% (074, 
099, 118, 138, 153, 180). GM PCB concentrations did not significantly differ in 
group 50% to 75% for both PAD diagnosed & participants with AS when compared 
to the normal group. In the final group ≥ 75%, a significant change was 
Cases/Non-cases Geometric Mean₂ (ng/g) (95% CI)
ABI < 0.7* 0.7 < ABI < 0.9* 0.9 < ABI < 1.3* ABI < 0.7 0.7 < ABI < 0.9 0.9 < ABI < 1.3 
Analyte₁
PCB074
< LOD to 50% 8 11 962 3.65 (3.15-4.23) 3.70 (3.48-3.94) 3.10 (3.02-3.18)
≥  50% 37 58 1904 17.68 (11.43-27.35) 11.04 (9.10-13.40) 11.20 (10.82-11.59)
PCB099
< LOD to 50% 11 13 1215 2.85 (2.44-3.33) 3.35 (3.17-3.54) 2.61 (2.55-2.68)
≥  50% 46 63 2549 13.06 (9.41-18.11) 7.14 (6.11-8.34) 8.03 (7.80-8.26)
PCB118
< LOD to 50% 16 14 1181 3.82 (3.06-4.78) 4.14 (3.85-4.45) 3.60 (3.52-3.68)
≥  50% 30 55 1686 28.26 (16.81-47.52) 15.26 (12.45-18.70) 14.09 (13.54-14.66)
PCB138
< LOD to 50% 11 16 1776 7.06 (4.42-11.29) 10.48 (7.94-13.83) 7.66 (7.41-7.92)
≥  50% 47 60 2018 45.30 (34.93-58.75) 34.77 (29.88-40.46) 35.53 (34.49-36.60)
PCB153
< LOD to 50% 10 12 1751 6.51 (3.86-10.96) 12.94 (8.76-19.12) 9.59 (9.23-9.96)
≥  50% 49 64 2050 64.87 (51.40-81.85) 54.29 (47.20-62.44) 50.47 (49.05-51.93)
PCB180
< LOD to 50% 11 15 1840 5.78 (4.02-8.32) 7.67 (5.71-10.30) 6.99 (6.69-7.29)
≥  50% 47 60 1953 51.69 (42.09-63.47) 44.85 (37.38-53.81) 41.63 (40.51-42.78)
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demonstrated through all the participants with PAD when compared to the normal 
group. However PCB congener 180 was only shown at being higher in AS 
participants compared to normal ones (Table 2.10). 
Table 2.10 Serum levels of PCBs (ng/g) in the study population, participants ≥ 40 years of 
age, NHANES 1999 – 2004.  
 
1 Lipid adjusted and log transformed polychlorinated biphenyls (ng/g) 
2 Geometric means calculated after applying NHANES sampling weight 
*ABI < 0.7 (PAD), 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal) 
 
Table 2.11 summarized adjusted odds ratios (ORs) and 95% confidence 
interval (CI) models for individual PCB congeners (074, 099, 118, 138, 153, and 
180) in two groups: < LOD to 50% & ≥ 50%. Adjusted models for < LOD to 50% 
showed no association between PCB exposure and PAD. However adjusted 
models for ≥ 50% showed significant associations for PCB congeners (074, 099, 
118, 138, 153, and 180) and PAD. Table 2.12 demonstrated adjusted ORs and 
95% CI models for individual PCB congeners (074, 099, 118, 138, 153, and 180) 
Cases/Non-cases Geometric Mean₂ (ng/g) (95% CI)
ABI < 0.7* 0.7 < ABI < 0.9* 0.9 < ABI < 1.3* ABI < 0.7 0.7 < ABI <0.9 0.9 < ABI < 1.3 
Analyte₁
PCB074
< LOD to 50% 8 11 962 3.65 (3.15-4.23) 3.70 (3.48-3.94) 3.10 (3.02-3.18)
50% to 75% 13 19 803 5.63 (4.91-6.44) 6.15(5.302-7.14) 6.05 (5.94-6.17)
≥ 75% 24 39 1101 31.81 (24.21-41.79) 15.95 (13.57-18.74) 16.83 (16.25-17.43)
PCB099
< LOD to 50% 11 13 1215 2.85 (2.44-3.33) 3.35 (3.17-3.54) 2.61 (2.55-2.68)
50% to 75% 19 41 1621 4.43 (4.22-4.65) 5.28 (4.78-5.83) 5.41 (5.33-5.50)
≥ 75% 27 22 928 21.30 (16.02-28.33) 12.38 (10.50-14.582) 15.72 (15.20-16.26)
PCB118
< LOD to 50% 16 14 1181 3.82 (3.06-4.78) 4.14 (3.85-4.45) 3.60 (3.52-3.68)
50% to 75% 4 15 614 5.87 (4.78-7.22) 7.04 (6.04-8.21) 7.24 (7.09-7.40)
≥ 75% 26 40 1072 34.52 (22.10-53.93) 19.09 (15.52-23.48) 21.64 (20.78-22.53)
PCB138
< LOD to 50% 11 16 1776 7.06 (4.42-11.29) 10.48 (7.93-13.83) 7.66 (7.41-7.92)
50% to 75% 19 25 817 21.63 (18.62-25.13) 20.40 (18.03-23.09) 21.70 (21.31-22.09)
≥ 75% 28 35 1198 75.44 (59.77-95.22) 47.29 (42.38-52.77) 54.04 (52.47-55.66)
PCB153
< LOD to 50% 9 11 1268 6.51 (3.86-10.96) 12.94 (8.76-19.12) 9.59 (9.23-9.96)
50% to 75% 11 19 588 30.98 (26.72-35.93) 32.36 (27.87-7.58) 30.73 (30.17-31.31)
≥ 75% 24 39 997 92.40 (73.10-116.79) 68.28 (61.11-76.30) 74.12 (72.12-76.17)
PCB180
< LOD to 50% 11 15 1840 5.78 (4.02-8.32) 7.67 (5.71-10.30) 6.99 (6.69-7.29)
50% to 75% 10 20 765 23.44 (20.60-26.68) 26.79 (23.64-30.35) 26.49 (26.03-26.96)
≥ 75% 36 40 1188 67.27 (56.16-80.57) 61.44 (51.93-72.715) 60.60 (59.00-62.25)
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in three groups: < LOD to 50%, 50 % to 75%, and ≥  75%. Adjusted models for 
PAD confounders; gender and PAD confounders; age, race, and PAD 
confounders; and gender, age, race, and PAD confounders showed a significant 
association between exposure and increased risk of PAD in groups 50% to 75% 
and ≥ 75%. Group < LOD to 50% showed no association.  Table 2.13 shows 
adjusted ORs and 95% CI models for individual PCB congeners in four groups: < 
LOD to 50%, ≥ 50%, < LOD to 75%, and ≥ 75%. Adjusted models in groups ≥ 50% 
& ≥ 75% showed association between higher exposure of PCBs and increased risk 
of PAD. 
In the adjusted model for PAD confounders (diabetes, smoking, & alcohol 
use) at   ≥  50% & ≥ 75%, dioxin-like PCBs were significantly associated with PAD 
[(OR: 2.04; 95% CI: 1.81 – 3.57), (OR:2.46; 95% CI:2.01 -11.87)] as well as non-
dioxin-like PCBs [(OR: 1.07; 95% CI: 1.02 – 32.59), (OR: 2.64; 95% CI: 1.62 – 
10.67)] . After adjusting the model for gender and PAD confounders, dioxin-like 
PCBs showed association with PAD [(OR: 1.35; 95% CI: 1.05 – 1.36), (OR: 3.35; 
95% CI: 1.35 – 10.36)] as well as non-dioxin-like PCBs [(OR: 2.38; 95% CI: 2.35 
– 29.40), OR: 2.59; 95% CI: 2.57 – 10.62)]. Adjusting the model for age, race, & 
PAD confounders the model demonstrated dioxin-like PCBs association with PAD 
[(OR: 1.95; 95% CI: 0.94 – 2.36), (OR: 2.95; 95% CI: 0.94 – 6.00)] together with 
non-dioxin-like PCBs [(OR: 2.07; 95% CI: 0.96 – 12.97), (OR: 2.37; 95% CI: 0.96 
– 6.97)]. After adjusting the model for gender, age, race, and PAD confounders; 
dioxin-like PCBs remained significantly associated with PAD [(OR: 1.68; 95% CI: 
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1.38 – 2.58), (OR: 3.88; 95% CI: 1.01 – 5.08)] as well as non-dioxin-like PCBs 
[(OR: 2.09; 95% CI: 2.09– 14.10), OR: 3.01; 95% CI: 1.10 – 8.13)].
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Table 2.11 Estimated ORs & 95% CI of PAD status by concentration of PCB levels among 
participants ≥ 40 years of age, NHANES 1999 - 2004 
 
 
¹ Lipid adjusted and log transformed polychlorinated biphenyls (ng/g) 
² Adjusted for PAD confounders (Diabetes, Smoking, and Alcohol Use) 
³ Adjusted for Gender, & PAD confounders  
⁴ Adjusted for Age, Race, & PAD confounders  
⁵ Adjusted for Gender, Age, Race, & PAD confounders 
*ABI < 0.7 (PAD), 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal) 
 
Table 2.12 Estimated ORs & 95% CI of PAD status by concentration of PCB levels among 
participants ≥ 40 years of age, NHANES 1999 - 2004 
 
 
¹ Lipid adjusted and log transformed polychlorinated biphenyls (ng/g) 
² Adjusted for PAD confounders (Diabetes, Smoking, and Alcohol Use) 
³ Adjusted for Gender, & PAD confounders  
⁴ Adjusted for Age, Race, & PAD confounders  
⁵ Adjusted for Gender, Age, Race, & PAD confounders 
*ABI < 0.7 (PAD), 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal) 
ABI < 0.7* 0.7 < ABI < 0.9* 0.9 < ABI < 1.3* Adjusted OR (95% CI)² Adjusted OR (95% CI)³ Adjusted OR (95% CI)⁴ Adjusted OR (95% CI)⁵
Analyte¹
PCB074
< LOD to 50% 8 11 962 1 1 1 1
≥  50% 37 58 1904 1.61 (0.64 - 8.65) 2.72 (1.72- 4.73) 2.63 (1.63 - 11.64) 2.76 (1.75 - 11.77)
PCB099
< LOD to 50% 11 13 1215 1 1 1 1
≥  50% 46 63 2549 2.92 (1.91 - 5.92) 2.95 (1.94 - 5.95) 1.91 (1.60 - 3.92) 1.95 (1.94 - 2.96)
PCB118
< LOD to 50% 16 14 1181 1 1 1 1
≥  50% 30 55 1686 2.26 (0.75 - 11.26) 3.31 (1.31 - 10.32) 4.08  (3.08 - 9.09) 4.17 (1.16 - 9.17)
PCB138
< LOD to 50% 11 16 1776 1 1 1 1
≥  50% 47 60 2018 1.38 (2.37 - 17.39) 3.39 (2.38 - 12.40) 3.71 (1.71 - 7.72) 3.73 (1.72 - 6.70)
PCB153
< LOD to 50% 10 12 1751 1 1 1 1
≥  50% 49 64 2050 3.45 (1.47 - 25.66) 4.64 (2.63 - 42.65) 2.16 (1.95 - 31.97) 3.33 (1.92 - 29.94)
PCB180
< LOD to 50% 11 15 1840 1 1 1 1
≥  50% 47 60 1953 2.33 (1.52 - 19.55) 3.49 (3.47 - 30.50) 2.00 (1.59 - 17.02) 2.89 (2.87 -17.90)
ABI < 0.7* 0.7 < ABI <0.9* 0.9 < ABI < 1.3* Adjusted OR (95% CI)² Adjusted OR (95% CI)³ Adjusted OR (95% CI)⁴ Adjusted OR (95% CI)⁵
Analyte₁
PCB074
< LOD to 50% 8 11 962 1 1 1 1
50% to 75% 13 19 803 1.78 (1.12 - 10.13) 2.11 (1.09 - 4.21) 1.35 (0.54 - 6.95) 2.45 (1.04 - 4.05)
≥ 75% 24 39 1101 2.02 (1.71 - 19.73) 3.26 (1.45 - 6.87) 2.59 (0.58 - 7.60) 3.80 (1.39 - 6.99)
PCB099
< LOD to 50% 11 13 1215 1 1 1 1
50% to 75% 19 41 1621 2.58 (1.38 - 4.59) 2.63 (1.62 - 3.63) 1.37 (0.13 - 2.85) 2.24 (0.44 - 3.45)
≥ 75% 27 22 928 3.50 (2.22 - 6.51) 2.58  (1.57 - 3.59) 1.32 (0.31 - 2.34) 2.46 (0.35 - 2.78)
PCB118
< LOD to 50% 16 14 1181 1 1 1 1
50% to 75% 4 15 614 2.21 (1.66 - 6.68) 2.80 (1.80 - 5.81) 1.76 (0.49 - 3.51) 3.00 (0.68 - 4.70)
≥ 75% 26 40 1072 2.50  (2.73 - 10.75) 2.89 (2.88 - 6.91) 2.59 (2.58 - 5.60) 3.79 (2.77 - 5.80)
PCB138
< LOD to 50% 11 16 1776 1 1 1 1
50% to 75% 19 25 817 1.75 (1.38 - 10.39) 2.39 (1.39 - 9.40) 1.76 (1.26 - 7.47) 2.48 (0.47 - 5.48)
≥ 75% 28 35 1198 2.03 (1.32 - 12.74) 3.75 (2.33 - 19.76) 2.28 (1.19 - 23.09) 3.10 (2.07 - 26.11)
PCB153
< LOD to 50% 9 11 1268 1 1 1 1
50% to 75% 11 19 588 3.69 (1.03 - 9.74) 5.64 (2.23 - 10.74) 3.07 (1.06 - 10.08) 3.04 (1.03 - 9.05)
≥ 75% 24 39 997 4.81 (2.24 - 13.17) 6.84 (3.23 - 14.45) 4.81 (1.70 - 13.73) 4.85 (2.64 - 10.66)
PCB180
< LOD to 50% 11 15 1840 1 1 1 1
50% to 75% 10 20 765 2.67 (1.23 - 8.68) 2.96 (1.65 - 30.66) 3.25 (1.66 - 25.68) 3.62 (1.61 - 19.62)
≥ 75% 36 40 1188 2.95 (1.87 - 10.33) 3.04 (2.23 - 14.26) 3.92 (0.86 - 16.90) 3.98 (0.66 - 21.71)
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Table 2.13 Estimated ORs (95% CIs) of PAD status by concentration of dioxin-like & non-
dioxin like PCB levels among participants ≥ 40 years of age, NHANES 1999 – 2004 
 
 
¹ Lipid adjusted and log transformed polychlorinated biphenyls (ng/g) 
² Adjusted for PAD confounders (Diabetes, Smoking, and Alcohol Use) 
³ Adjusted for Gender & PAD confounders  
⁴ Adjusted for Age, Race, & PAD confounders  
⁵ Adjusted for Gender, Age, Race, & PAD confounders 
*ABI < 0.7 (PAD), 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal) 
 
Discussion 
 This cross sectional study representing a sample of the United States 
demonstrated that higher levels of PCB concentration were associated with 
participants defined with PAD and atherosclerosis in the general population. We 
assessed 6 individual PCB congeners, the sum of dioxin-like PCBs, and the sum 
of non-dioxin like PCBs. Overall analysis of geometric mean levels of PCBs 
represented by participants identified with PAD, atherosclerosis, age, race, and 
various covariates was done to assess PCB concentrations in subpopulations. All 
PCB congeners showed a higher concentration level in both PAD participants and 
at AS when comparing to the normal population. Although to our knowledge this is 
the first study investigating PCB association with PAD and AS, our results adds 
developing evidence to the environmental exposure of PCBs similar to the effects 
of BPA, another type of endocrine disrupting chemical in cardiovascular disease 
(Lang et al., 2008; Melzer et al., 2010). Furthermore because PAD is a subclinical 
ABI < 0.7* 0.7 < ABI < 0.9* 0.9 < ABI < 1.3* Adjusted OR (95% CI)⁴ Adjusted OR (95% CI)⁵ Adjusted OR (95% CI)⁶ Adjusted OR (95% CI)⁷
Analyte¹
Dioxin-like PCBs_50²
< LOD to 50% 4 6 71 1 1 1 1
≥ 50% 45 69 1342 2.04 (1.81 - 3.57) 1.35 (1.05 - 1.36) 1.95 (0.94 - 2.36) 1.68 (1.38 - 2.58)
Dioxin-like PCBs_75²
< LOD to 75% 10 15 90 1 1 1 1
≥ 75% 58 76 1288 2.46 (2.01 - 11.87) 3.35 (1.35 - 10.36) 2.95  (0.94 - 6.00) 3.88 (1.01 - 5.08)
Non-dioxin-like PCBs_50³
< LOD to  50% 15 18 65 1 1 1 1
≥ 50% 61 55 1710 1.07 (1.02 - 32.59) 2.38 (2.35 - 29.40) 2.07 (0.96 - 12.97) 2.09 (2.09 - 14.10)
Non-dioxin-like PCBs_75³
< LOD to 75% 6 4 951 1 1 1 1
≥ 75% 59 76 828 2.64 (1.62 - 10.67) 2.59 (2.57 - 10.62) 2.37 (0.96 - 6.97) 3.01 (1.10 - 8.13)
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marker for atherosclerosis, our findings may elucidate that possible effects of 
PCBs on atherosclerosis may be an essential mechanism previously reporting an 
association between PCB exposure and the development of obesity and obesity-
associated atherosclerosis (Arsenescu et al., 2008).   
Polychlorinated Biphenyls are a group of man-made organic chemicals that 
consist of chlorine, hydrogen, and carbon atoms. Today PCBs can still be released 
in the environment from illegal dumping of PCB wastes, burning wastes in 
industrial and municipal incinerators, leaks from electrical transformers containing 
PCBs, and improper or poorly maintained hazardous sites containing PCBs (EPA). 
While there has not been any previously studies done in NHANES linking PCB 
exposure to PAD and AS recent studies have linked exposure to BPA to peripheral 
arterial disease (Shankar et al., 2012) and heart disease (Melzer et al., 2010).  
 Numerous lines of evidence suggest that a link between levels of PCB 
concentrations and PAD and/or AS may be biologically conceivable. Significant 
associations between PCBs, lipids, age, BMI, and CVD in a Native American 
population demonstrate a consistency with a model in which age is considered 
both a biological driving mechanism and exogenous explanatory variable 
(Goncharov et al., 2008). Dioxin-like PCB 126 effects CVD risk factors on female 
experimental rodents such as blood pressure, heart weight, and serum cholesterol 
(Lind et al., 2004). Furthermore higher levels of PCB concentration in HDL 
demonstrated links to CVD (Ljunggren et al., 2014). Previously we have reported 
planar and coplanar PCBs induce expression of various genes compared to 
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estradiol that have biological relevance to signaling in pulmonary vascular lesions 
(Felty et al., 2010). Additionally, ID3 a molecule that has been demonstrated to be 
involved in vascular diseases has provided evidence linking its vital role in 
regulating both vascular endothelial cell survival and microvascular lesion 
development by endocrine disrupting chemicals such as PCB153 (Das & Felty., 
2014).  
 Our study includes a nationally representative sample of the United States 
population and provides a rigorous methodology of collecting, analyzing, and 
having multiple confounding data point’s accessible to the public. (NCHS 2010a, 
2010b). Further strengths include availability of biological measurements of 
endocrine disrupting chemicals and oversampling of minority populations making 
it possible to have a complete representation of the US population. However a 
limitation that we have on our study is since it is a cross-sectional study, it makes 
it difficult to validate the exposure ensued the overall outcome. Additionally 
observed associations could be potentially confounded by lack of data on 
geographical location of family history and/or geographic location of some 
variables.  
Conclusion 
 In a nationally representative sample of the U.S. population higher levels of 
PCB exposure were associated with increased risk of PAD as well as 
atherosclerosis subsequently adjusting for covariate factors. While our results 
must be established in other studies, they provide preliminary evidence that 
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environmental exposure to PCBs may contribute to increased risk of PAD and/or 
AS. 
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CHAPTER IV 
MANUSCRIPT 3 
Association of endocrine disrupting chemical exposure in Peripheral Arterial 
Disease (PAD) Among the U.S. Population: NHANES 1999 – 2004 
Abstract 
Background. Recent reports have continuously shown that the human population 
get exposed to a wide range of endocrine disrupting chemicals. In particular 
phthalates & bisphenol A (BPA) have been detected in more than 90% of urine 
and blood samples collected (Silva et al 2004; Woodruff et al 2011; Calafat et al 
2008). Although previous reports from various data have demonstrated 
association between phthalates & BPA with various diseases the bridge between 
phthalates & BPA with peripheral arterial disease is limited.  
Objectives. The purpose of this study is to examine association between exposure 
to endocrine disrupting chemicals (EDCs) & peripheral arterial disease (PAD) in a 
nationally represented sample of the U.S. population.   
Methods. We utilized participants in the National Health and Nutritional 
Examination Survey (NHANES) in 1999 - 2004. We estimated associations 
between exposure to EDCs (phthalates in 1999 - 2004 & bisphenol A in 2003 – 
2004) respectively and PAD using complex survey and logistic regression models 
adjusted for potential confounders. 
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Results. Individual analyses showed phthalate metabolites: MnBP and MBzP 
alongside BPA to be higher among participants with PAD and AS when compared 
to the rest of the study population. Adjusted models for PAD confounders showed 
association between phthalate metabolites ≥ LOD and participants with PAD and 
AS: MnBP (OR: 1.33; 95%: 1.00 – 2.34); MBzP (OR: 1.16; 95% CI: 1.08 – 2.01) 
and BPA (OR: 1.22; 95% CI: 1.02 – 5.07). Furthermore after adjusting the model 
for gender and PAD confounders; age, race, and PAD confounders; and gender, 
age, race, and PAD confounders we demonstrated association between phthalate 
metabolites & BPA with PAD participants and AS.  
Conclusion. Our findings suggest a relationship between higher environmental 
exposure of certain phthalate metabolites & BPA and increased risk of peripheral 
arterial disease (PAD) and atherosclerosis (AS).  
Key words: ankle – brachial index, bisphenol A, endocrine disrupting chemicals, 
NHANES, peripheral arterial disease, phthalates 
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Introduction  
The US EPA (United States Environmental Protection Agency) outlines 
endocrine disrupting chemicals (EDCs) as “agents that interferes with the 
synthesis, transport, elimination, binding, or secretion of natural hormones in the 
body that are responsible for the maintenance of reproduction, homeostasis, 
behavior, and/or development.” (Kavlock et al., 1996). While numerous chemicals 
have EDC activity the most studied chemicals today include phthalates and 
bisphenol A (BPA). Phthalates consist of a wide variety of products that include 
medical tubing, cosmetics, plastics, and coatings. (Gore et al., 2015). Bisphenol A 
is used in products such as toys, food packaging, manufacturing, and other 
applications. Due to the fact that essentially everyone uses these day-to-day 
products, the overall population is continually exposed. (Meeker and Ferguson. 
2011). While earlier research has concentrated on the role of phthalates and 
bisphenol A (BPA) in cancer, reproductive, and developmental health problems; 
existing research has established associations between diabetes, obesity, and 
cardiovascular disease (Anway et al. 2005; Lang et al. 2008; Melzer et al. 2010; 
Morgan et al., 2016). Although these establishments have been seen throughout 
the literature it is warranted to extend that investigation to peripheral arterial 
disease in order to further bridge the gap in knowledge  
In this study, we examined the independent association between individual 
phthalates and bisphenol A (BPA) with diagnosis of peripheral arterial disease and 
participants with atherosclerosis with participants in the NHANES (National Health 
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and Nutrition Examination Survey) 3-year cycle for phthalates: 1999 – 2004 and 1-
year cycle 2003-2004 for bisphenol A (BPA). The aim of this study is to assess: 1) 
the mean phthalate levels in PAD defined participants and defined with 
atherosclerosis compared to non-diagnosed participants; and 2) the mean 
bisphenol A (BPA) levels in PAD defined participants and atherosclerosis 
compared to non-diagnosed participants, and 3) the association between higher 
EDC exposure and increased risk of PAD/AS respectively.  
Methods 
Study design and population. NHANES survey encompasses stratified 
multistage probability sample representative of the civilian non-institutionalized 
U.S. population. The study is recognized based on data from NHANES 1999 -
2004. Selection was based on individuals within households, households, blocks, 
counties and included the oversampling of non-Hispanic blacks and Mexican 
Americans in order to deliver consistent evaluations of these groups. Participants 
provided written informed consent before their participation. Additionally approval 
was acquired from the Human Subjects Committee in the U.S. Department of 
Health and Human Services. ABI measurements which is a subclinical measure of 
atherosclerosis (Criqui et al. 1992; Newman et al. 1993), were acquired for the 
subsample of participants ≥ 40 years of age. The current study sample consisted 
of participants ≥ 40 years of age among whom endocrine disrupting chemicals was 
available. This resulted in participants (461), of whom had PAD and participants 
(390) whom were atherosclerosis defined in NHANES 1999 – 2004 and 178 PAD 
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defined participants; 94 atherosclerosis participants; and 1850 normal participants 
respectively. Subjects who were omitted because of missing covariates were in 
general comparable to the NHANES group in terms of sex, age, race/ethnicity, and 
education (data not shown). Secondary examination of the nationally collected 
data was done using variables of interest, which were only measured concurrently 
during the three NHANES cycles from 1999 - 2000, 2001 - 2002, and 2003 - 2004. 
NHANES uses a multifaceted sampling design (multistage, probability, cluster and 
stratified) for continuous collection and release of 2-year cross-sectional data sets. 
Approval for these suitable examinations and laboratory testing were given to 
NHANES by the CDC/ATSDR institutional review board of the CDC. The current 
study was considered exempt from review by the local institutional review board.  
Peripheral Arterial Disease (PAD) diagnosis. The NHANES ABI is regularly 
calculated, verified, and released by the National Center for Health Statistics. 
Systolic pressure is measured on the right arm (brachial artery) and both ankles 
(posterior tibial arteries). If the participant has one of the following: 1) a rash; 2) 
open wound on the right arm; 3) dialysis shunt; 4) right-sided radical mastectomy; 
or any extra condition that would obstruct with correct measurement or cause 
discomfort to the participant, the left arm is utilized for the brachial pressure 
measurement. Systolic blood pressure is measured twice at each site for 
participants 40-59 years old and once at each site for participants ≥ 60 years old 
and older. If a health technician cannot obtain a reading at a site they may attempt 
an additional reading at the same site after a short-term resting period. The right 
ABPI was obtained by dividing the mean systolic blood pressure in the right ankle 
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by the mean blood pressure in the arm. The left ABPI was obtained by dividing the 
mean systolic blood pressure in the left ankle by the mean blood pressure in the 
arm. The mean blood pressure value for the arm and ankles are computed based 
on the first and second reading at each site. As the second reading for all 
participants ≥ 60 years old is missing the mean values are in fact the first recorded 
blood pressure reading at a site. This may furthermore be correct for participants 
40-59 years old who have a missing value for the first or second blood pressure 
reading. Individuals are omitted from the exam if they weigh over 400 pounds 
(weight limitations of equipment) or have bilateral amputations. Additionally to 
some participants who were eligible for the exam (≥ 40 years old) might not have 
received the exam due to various reasons including: casts, ulcers, dressings, or 
other conditions of the participant interfered with testing; participant could not 
understand the test instructions or became ill & the test could not be performed; 
there was an equipment failure; participant refused; participant came late or left 
early from the MEC & the LED exam could not be performed; and some other 
reason. As a result, these eligible individuals will have missing data for the ABPI 
variables. Peripheral arterial disease diagnosis was defined as having an ankle 
brachial index (ABI) < 0.7. Values 0.9 < ABI < 1.3 were considered normal. 
Individuals whom demonstrated 0.7 < ABI < 0.9 was defined as atherosclerosis.  
Measurements of phthalates & bisphenol A. Both phthalates and bisphenol A 
were calculated in urine by the SPE (solid phase extraction) coupled to reverse 
phase HPLC-MS/MS (high performance liquid chromatography-tandem mass 
spectrometry). Laboratory methods and quality control were reliable across survey 
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years and in which documentation is available online (CDC, 2012). Overall we 
investigated 7 phthalate metabolites measured in NHANES years 1999 - 2004: 
mono-n-butyl phthalate (MnBP), mono-cyclohexyl phthalate (MCHP), mono-ethyl 
phthalate (MEP), mono-2-ethylhexyl phthalate (MEHP), mono-isobutyl phthalate 
(MiBP), mono-n-octyl phthalate (MOP), and mono-bezyl phthalate (MBzP). BPA 
(bisphenol A) was the only phenol included in this study. In order to adjust for urine 
dilution, we divided all phthalate metabolites and BPA by urinary creatinine 
concentration and used the resultant corrected creatinine concentrations (mg/g) 
for all of our analyses. Urine samples with creatinine that represented levels > 300 
mg/dL or < 30 mg/dL were excluded in the analysis because the sample(s) were 
over-concentrated for an accurate examination (Sata et al., 1995). Furthermore we 
provided a limit of detection (LOD) variable for each phthalate metabolite and BPA 
in the datasets. The variable is defined with two values: “1” represents the result 
was below the limit of detection and “2” represents the result was equal or above 
the limit of detection.  
Covariates. We considered a range of confounders based on well-established risk 
factors for peripheral arterial disease and review of the literature. The resultant 
confounders were self-reported in the questionnaire interviews or taken as 
laboratory measurements. The demographic variables of gender (men/women), 
race (Mexican American, Other Hispanic, Non-Hispanic White, Non-Hispanic 
Black, and other race) and age (≥ 40-59, 60-74, and ≥ 75) were obtained during 
the NHANES home interview (CDC, 2012). Others obtained include: smoking, BMI 
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(18.5 to < 25, 25 to <30, & ≥ 30), diabetes (yes/no), estradiol levels, sex hormone 
binding globulin, testosterone, and education. 
Statistical Analysis. Analysis were performed using SAS 9.4 (SAS Institute Inc.; 
Cary, NC, USA). Appropriate subsampling weights were calculated according to 
the National Center for Health Statistics guidelines to adjust for oversampling of 
minority groups (CDC, 2013b). All urinary chemicals and metabolites were log 
transformed and creatinine adjusted. PROC SURVEYMEANS was used to 
account for the complex sampling design of NHANES and furthermore obtain 
means (weighted), 95% confidence intervals, and standard errors of individual 
phthalate metabolites and BPA. Age was divided into three groups (≥ 40-59, 60 – 
74, and ≥ 75 years old). A two-sided student t-test was measured using PROC 
SURVEYREG to test if the mean EDC (phthalates/BPA) levels between 
participants who were defined with PAD, AS, and normal participants were 
significantly different. Geometric mean (GM) levels and geometric standard errors 
(GSE) were reported for peripheral arterial disease status, AS status, age at 
interview, and race/ethnicity for all participants with individual phthalate 
metabolites & BPA levels. Age was divided into three groups (≥ 40-59 years, 60-
74 years, and ≥ 75 years) that were selected based on the age distribution of PAD 
cases, cases of AS, and normal cases in the population. Race/ethnicity was 
divided into five groups (Mexican American, other Hispanic, Non-Hispanic White, 
Non-Hispanic Black, and other race). 
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Results 
Phthalate and Bisphenol A Descriptive Statistics. The study population for 
phthalates includes 3,489 men and 3,125 women from NHANES cycles 1999 – 
2004 with available data and who are either identified with peripheral arterial 
disease (n = 461), atherosclerosis defined (n = 390), or as a normal participant (n 
= 5773) as shown in Table 3.1. Bisphenol A population from NHANES 2003 – 2004 
includes 868 men and 946 women from NHANES cycle 2003 – 2004 with available 
data (Table 3.2). Overall 178 participants are diagnosed with PAD; 94 whom are 
at identified with atherosclerosis; and 1850 whom are considered normal 
participants. The majority of the participants in the phthalate population was Non-
Hispanic White: 268 (3.72%) for PAD participants; 236 (4.90%) for participants 
with AS; and 3,125 (69.64%) normal diagnosed participants. Table 3.3 displays 
Cases/Non-Cases, geometric means (GM), and geometric standard error (GSE).  
GM of particular phthalate metabolites were significantly higher in participants 
diagnosed with PAD and AS when compared to normal diagnosed participants. 
Those phthalate metabolites include: MnBP (27.12 & 24.99 vs. 24.16) and MBzP 
(13.63 & 12.21 vs. 11.69). Furthermore, BPA also showed significant higher GM 
in diagnosis of PAD and AS when compared to normal participants (4.65 & 7.67 
vs. 2.73). Table 3.4 illustrates estimated odds ratios (ORs) and 95 % confidence 
intervals (CIs) for phthalate metabolites and bisphenol A adjusted for 1) PAD 
confounders (diabetes, smoking, and alcohol use); 2) gender and PAD 
confounders 3) age, race, BMI, & PAD confounders; and 4) gender, age, race, BMI 
and PAD confounders. In the PAD confounders adjusted model phthalate 
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metabolites: MnBP (OR: 1.33; 95% CI: 1.00 – 2.34) and MBzP (OR: 1.16; 95% CI: 
1.08 – 2.01) showed significant association with PAD and AS when exposure is ≥ 
LOD. Furthermore bisphenol A also showed significant association with PAD and 
AS when exposure is ≥ LOD (OR:  1.22; 95% CI: 1.02 – 5.07). In the gender and 
PAD confounders adjusted model phthalate metabolites: MnBP (OR: 1.83; 95% 
CI: 1.00 – 2.34); MCHP (OR: 1.54; 95% CI: 1.00 – 2.10), MEP (OR: 1.01; 95% CI: 
0.44 -1.09) and MBzP (OR: 1.76; 95% CI: 1.58 – 2.91) showed significant 
association with PAD and AS when exposure is ≥ LOD. BPA showed significant 
association with PAD and AS when exposure is ≥ LOD (OR: 2.89 95% CI: 1.50 – 
10.19). The age, race, BMI, and PAD confounders model demonstrated that 
phthalate metabolites: MnBP (OR: 1.33; 0.89 – 2.95); MCHP (OR: 1.39; 95% CI: 
1.00 – 1.65); and MiBP (OR: 1.48; 95% CI: 1.12 – 1.87) showed significant 
association with PAD and AS when exposure is≥ LOD.  In the final model adjusted 
for gender, age, race, BMI, and the PAD confounders phthalate metabolites MCHP 
(OR: 1.34; 95% CI: 1.22 – 1.59) and MiBP (OR: 1.41; 95% CI: 0.99 – 1.83) showed 
significant association with PAD and AS when exposure is ≥ LOD. BPA also 
showed significant association (OR: 3.02; 95% CI: 0.14 – 12.15) with PAD and AS 
when exposure is ≥ LOD.  
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Table 3.1 Descriptive statistics for PAD & selected covariates among participants ≥ 40 years 
of age, NHANES 1999 – 2004.  
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Estimated percent distribution after applying NHANES sampling weights 
*ABI < 0.7 (PAD). 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal) 
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Table 3.2 Descriptive statistics for PAD & selected covariates among participants ≥ 40 years 
of age with bisphenol A (BPA) measurements NHANES 2003 - 2004. 
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Estimated percent distribution after applying NHANES sampling weights 
*ABI < 0.7 (PAD). 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal) 
 
 
Table 3.3. Geometric mean of urinary phthalate metabolites and BPA levels above the LOD 
by PAD status among participants ≥ 40 years of age, NHANES 1999 - 2004 
 
¹ Log transformed and creatinine corrected phthalate metabolites (ng/mg); NHANES 1999 - 2004 
² Log transformed and creatinine corrected BPA (ng/mg); NHANES 2003 - 2004 
³ Geometric means calculated after applying NHANES sampling weights 
*ABI < 0.7 (PAD), 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal) 
Cases/Non-Cases Geometric Mean³ (ng/g) (GSE)
ABI < 0.7* 0.7 < ABI < 0.9* 0.9 < ABI < 1.3* ABI < 0.7 0.7 < ABI <0.9 0.9 < ABI < 1.3 
Phthlate Metabolites¹
MnBP 384 320 5198 27.12 (22.21, 33.10) 24.99 (20.58, 31.12) 24.16 (23.24, 25.12)
MCHP 456 250 5196 0.55 (0.50, 0.60) 0.62 (0.55, 0.70) 0.58 (0.56, 0.60)
MEP 175 223 5504 127.33 (102.40, 158.34) 120.80 (98.68, 147.86) 136.31 (129.59, 143.38)
MEHP 210 520 5172 3.58 (2.87, 4.45) 2.97 (2.48, 3.55) 3.44 (3.28, 3.62)
MiBP 180 869 4853 1.05 (0.99, 1.11) 1.03 (0.97, 1.09) 1.04 (1.01, 1.07)
MOP 384 320 5198 1.22 (1.18, 1.27) 1.21 (1.18, 1.25) 1.23 (1.21, 1.24)
MBzP 400 380 5122 13.63 (11.26, 16.50) 12.21 (10.13, 14.71) 11.69 (11.13, 12.28)
Bisphenol A²
BPA 142 77 1427 4.65 (3.27 - 6.04) 7.67 (5.75 - 9.59) 2.73 (2.64 - 5.82)
 99 
 
 
Table 3.4 Estimated ORs (95% CIs) of PAD status by concentration of creatinine adjusted 
urinary phthalate metabolites & BPA among participants ≥ 40 years of age, NHANES 1999 – 
2004 & 2003 – 2004. 
 
¹ Log transformed and creatinine corrected phthalate metabolites (ng/mg); NHANES 1999 - 2004 
² Log transformed and creatinine corrected BPA (ng/mg); NHANES 2003 - 2004 
³ Adjusted for PAD confounders (Diabetes, Smoking, and Alcohol Use) 
⁴ Adjusted for Gender & PAD confounders 
⁵ Adjusted for Age, Race, & PAD confounders 
⁶ Adjusted for Gender, Age, Race, & PAD confounders 
*ABI < 0.7 (PAD), 0.7 < ABI < 0.9 (AS), & 0.9 < ABI < 1.3 (Normal)
 
Discussion. In this cross-sectional study of participants aged ≥ 40 years old, we 
separately investigated 7 individual phthalate metabolites and BPA in association 
with peripheral arterial disease (PAD) and atherosclerosis (AS). In participants with 
detectable levels of phthalates and BPA, higher exposures were found in 
participants diagnosed with PAD and AS when compared to normal participants 
and phthalate metabolites: MnBP and MBzP. Furthermore when ORs and 95% CI 
models were adjusted for various models higher exposure phthalate metabolites 
& BPA (≥ LOD) showed significant association with participants diagnosed with 
PAD and AS [1) PAD confounders model: MnBP and MBzP; 2) gender and PAD 
confounders model: MnBP, MCHP, MEP, and MBzP 3) age, race, BMI, and PAD 
ABI < 0.7* 0.7 < ABI < 0.9* 0.9 < ABI < 1.3* Adjusted OR (95% CI)³ Adjusted OR (95% CI)⁴ Adjusted OR (95% CI)⁵ Adjusted OR (95% CI)⁶
Phthlate Metabolites¹
MnBP
< LOD 294 239 4032 1 1 1 1
≥  LOD 90 81 1166 1.33 (1.00 - 2.34) 1.83 (1.00 - 2.34) 1.33 (0.89 - 2.95) 0.96 (0.85 - 1.99)
MCHP
< LOD 400 341 5400 1 1 1 1
≥  LOD 10 3 86 0.54 (0.25 - 2.10) 1.54 (1.00 - 2.10) 1.39 (1.00 -1.65) 1.34 (1.22 - 1.59)
MEP
< LOD 49 44 603 1 1 1 1
≥  LOD 360 297 4876 0.99 (0.44 - 1.05) 1.01 (0.44 - 1.09) 0.85 (0.55 -1.09) 0.98 (0.51 - 1.28)
MEHP
< LOD 407 339 5429 1 1 1 1
≥  LOD 3 1 48 0.72 (0.40 - 0.93) 0.92 (0.40 - 0.93) 0.94 (0.92 - 0.95) 0.92 (0.93 - 0.96)
MiBP
< LOD 410 341 5457 1 1 1 1
≥  LOD 7 13 21 0.79 (0.18 - 0.80) 0.59 (0.18 - 0.80) 1.48 (1.12 - 1.87) 1.41 (0.99 - 1.83)
MOP
< LOD 410 341 5489 1 1 1 1
≥  LOD 10 9 34 0.95 (0.95 -1.60) 0.97 (0.95 - 1.60) 0.92 (0.70 - 1.49) 0.98 (0.47 - 1.57)
MBzP
< LOD 131 103 1916 1 1 1 1
≥  LOD 277 236 3551 1.16 (1.08 - 2.01) 1.76 (1.58 - 2.91) 0.91 (0.84 - 0.97) 1.73 (0.92 - 3.18)
Bisphenol A²
BPA
< LOD 8 8 118 1 1 1 1
≥  LOD 141 71 1315 1.22 (1.02 - 5.07) 2.89 (1.50 - 10.19) 2.17 (1.65 - 7.17) 3.02 (0.14 - 12.15)
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confounders model: MnBP, MCHP, and MiBP and 4) gender, age, race, BMI, & 
PAD confounders model: MCHP, MiBP, and MBzP]. 
Previous epidemiological studies showed that phthalate metabolite MMP 
was associated with atherosclerotic plaques in an inverted U-shaped manner (low 
levels of MMP have an effect) independently of cardiovascular risk factors. Some 
phthalates and BPA were also correlated to the echogenicity of the plaques, 
suggesting a role for plaque-associated chemicals in atherosclerosis (Lind and 
Lind. 2011). Furthermore irregular associations between phthalates and 
hyperlipidemia were shown with self-reported diabetes and CVD in Shanghai 
adults (Dong et al. 2017). BPA levels were demonstrated to be significantly 
associated with PAD before and after adjusting for confounders (Shankar et al. 
2012). There is additional evidence that individuals with higher urinary BPA levels 
are more inclined to suffer from general or abdominal obesity, hypertension, and 
diabetes when compared with individuals having lower urinary concentrations 
(Rancière et al. 2015). Common carotid artery intima-media thickness (CIMT) 
measured by ultrasonography is a recognized indicator of subclinical 
atherosclerosis and independent predictor of myocardial infarction, coronary 
events, and stroke (Bots et al. 1997; Hodis et al. 1998; Su et al. 2006; Chien et al. 
2008; Su et al. 2012). It was reported that in a cross-sectional investigation of a 
representative population sample of subjects aged 60 - 80 years old showed a 
significant association between small changes in IMT and both symptomatic and 
asymptomatic peripheral arterial disease (Allan et al. 1997). Lin et al further 
determined the relationship between levels of BPA and carotid-media thickness 
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(CIMT) and discovered higher serum concentrations of BPA were associated with 
increased CIMT in a cross-sectional study of adolescents and young adults (Lin et 
al. 2015). Although previous studies and our current study show significant 
associations between EDCs (phthalates and BPA) with peripheral arterial disease 
further research is warranted to elucidate mechanisms of these associations.  
The main strengths of our study include oversampling of minority 
populations that make it highly representative and generalizable to the United 
States population and availability of biological measurements of environmental 
pollutants. Additionally this study is nationally representative and uses stringent 
methods to collect available data on confounders. One limitation of this study is 
since it is a cross – sectional design with self - reported data, it does not permit for 
causal inferences to be concluded. Self – reported data increases the likelihood of 
misclassification bias of cases and controls contributing to the possibility of 
incorrectly or undiagnosed reported PAD and/or AS cases. Another limitation is 
that BPA measurements are more likely to result in misclassification due to 
variability.  
Conclusion 
Based on our analysis of phthalate metabolites from 1999 – 2004 and BPA from 
2003 – 2004 higher exposure of particular phthalate metabolites and BPA did 
demonstrate association with participants who are diagnosed with PAD alongside 
AS. Given earlier and existing research demonstrates exposure to other EDCs 
such as polychlorinated biphenyls are associated with cardiovascular disease, it is 
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biologically plausible that exposure to phthalates and BPA may contribute to higher 
risk of the disease.  Our research findings coupled with previous epidemiological 
evidence concerning EDCs and peripheral arterial disease warrants the necessity 
for prospective future studies.  
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CHAPTER V 
MANUSCRIPT 4 
Genome-wide gene expression profiling of Inhibitor of DNA 
binding/Differentiation-3 (ID3) candidate targets in vascular-intimal lesions 
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Abstract 
Obliterative and proliferative vascular intimal lesions are categorized by 
perturbations of cellular constituents & their normal patterning of vessels. The 
pathophysiologic pathways that transition to these end-stages are infrequently 
distinct. Because they may suggest the normal assembly of vessels during 
development, developmental biology, which combines embryologic analyses of 
cellular origins, lineage, and cell–cell interactions with genetic studies, holds the 
prospect of revealing the role of individual genes in the pathogenesis of vascular 
disease. The Inhibitor of DNA binding/Differentiation-3 (ID3), a member of the ID 
family of transcriptional regulators, has been shown to play a role in lipoxygenase 
(12/15-LO) which is known to produce pro-inflammatory alterations in blood 
vessels that lead to the development of atherosclerosis. Furthermore studies have 
shown overexpression of ID3 increasing OCT4 and SOX2 expression in 
microvascular endothelial cells. Therefore we determined the functional role of ID3 
and ID3 candidate target genes in obliterative and proliferative vascular-intimal 
lesions. We performed a meta-analysis on published whole genome microarray 
datasets comparing transcriptional patterns of blood cells & tissue samples to 
controls. Bioinformatics network analysis identified statistically the most 
overrepresented processes and signaling pathways. Deciphering the pattern & 
role of genes involved with ID3 & ID3 targets in obliterative and proliferative 
vascular diseases may provide a new model by which ID3 may contribute to the 
growth regulation of these vascular intimal-lesions. Keywords: bioinformatics, 
ID3, vascular diseases, vascular-intimal lesions 
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Introduction 
Although poorly understood, obliterative & proliferative vascular-intimal 
lesions are a significant health problem that may lead to blocked blood vessels 
and can cause threatening end organ damage such as ischemic stroke, blindness, 
right-sided heart failure, or myocardial infarction. Obliterative & proliferative 
vascular-intimal lesions manifest in numerous vascular diseases such as 
arteriosclerosis, idiopathic pulmonary arterial hypertension, peripheral arterial 
disease, and lymphangioleiomyomatosis. The endothelium plays an essential role 
in classifications of obliterative and proliferative diseases. A vital foundation of 
vascular biology is that the lining of the endothelial is dynamically a changeable 
interface. This is locally responsive to multiple types of stimuli that can originate 
from the emigrating & circulating cells and/or neighboring tissues and thus can 
actively participate in the physiologic variation or vascular dysfunction of a certain 
section of the vasculature. The endothelium appears to be best suited to function 
in this capacity, given its distinctive anatomic location between tissue & blood and 
ability to generate various biological effectors such as cytokines, growth 
stimulators & inhibitors, vasoactive peptides, pro- & anti-coagulants, and nitric 
oxide. Disruption in the production or interactions of these different mediators 
appear to effect various vital functions of the endothelium, specifically its role as a 
non-thrombogenic vessel for antithrombotic, growth inhibitory, and anti-
inflammatory activities; and blood that aids to preserve the integrity of the vascular 
wall, when facing injury-related stimuli and various disease risk factors (Fishman 
et al. 1998).  
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Conceivably the most well-known studied model of activation of vascular 
endothelium are the effects of pro-inflammatory cytokines such as tumor necrosis 
factor (TNF) and interleukin-1 (IL-1). These have provided a widely used 
experimental model, which have been studied at the tissue level (various diseased 
human tissues & animal models) and cellular level (receptors, genetic regulatory 
events, & signaling pathways) (Fishman et al.1998; Cuthins et al. 2012; Sakurai et 
al. 2004). Additionally, the effects of the biochemical dynamisms produced by 
pulsatile blood flow including pressures, wall shear stress, & cyclic strains on 
endothelial structure and function as been seen as another model of vascular cell 
activation. The capability of laminar shear stresses to up-regulate atheroprotective 
endothelial genes and significantly influence the functional phenotype of 
endothelial cells indicates that this model of activation may be playing a significant 
pathophysiologic role. Although the evidence implicates tissue and cellular levels 
as an influence on obliterative & proliferative vascular intimal-lesions, the 
pathogenesis is far from clarified to date.  
At the molecular level, Inhibitor of DNA binding/Differentiation-3 is a 
member of the ID family (ID1-ID4) of helix-loop-helix proteins encoded by an 
immediate-early gene responsive to mitogenic signals and oxidative stress. 
Besides the regulation of cell differentiation, ID proteins are also positive regulators 
of cell growth and play a major role in neovascularization. An increasing body of 
evidence suggests that ID3 may be involved in disruptions characterized by 
abdominal obesity, insulin resistance, hyperglycemia, dyslipidemia, and 
hypertension. Interactions across multiple organ systems that contribute to 
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disruption presents a challenge to ongoing research attempting to elucidate 
biological mechanisms of chronic disease such as vascular. For example, insulin 
resistance and systemic low-grade inflammation result from complex interactions 
between the vasculature, metabolic tissue, and immune cells. In the vasculature, 
ID3 is essential to embryonic vasculogenesis and endothelial cell activation 
(Sakurai et al., 2004; Felty & Porther, 2008; Elen et al., 2015). ID3 involvement in 
vascular disease has been studied together with the lipoxygenase (12/15-LO), 
which is a vital mediator of VSMC growth and its growth-promoting effects were 
shown to be mediated by ID3 transcription (Taylor et al., 2015). Increased 
expression of 12/15-LO in the vessel wall enhanced ID3-dependent cell 
proliferation, fibronectin deposition, and neo-intimal formation (Taylor et al., 2015). 
Population established studies have found an SNP (single nucleotide 
polymorphisms) rs11574 in the coding region of the human ID3 gene associated 
with subclinical atherosclerosis in the Diabetes Heart study (Doran et al., 2010). 
Furthermore two cohorts determined the link between the SNP directly with 
coronary artery pathology. ID3 has also been shown as a key mechanism of high 
fat diet stimulated through visceral adipose VEGFA expression, depot expansion 
and micro-vascular blood volume (Cuthins et al., 2012). ID3 is important to obesity 
because it has been suggested to stimulate angiogenesis, a major factor of HFD 
(high-fat diet)-induced visceral adiposity (Cuthins et al., 2012).  
Our research has recently shown that ectopic overexpression of ID3 
increased OCT4 and SOX2 expression in endothelial cells as well as resulted in a 
population of cells that were positive for the molecular stemness signature CD133+ 
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VEGFR3+ CD34+ (Das et al., 2015). These endothelial stem cells were 
morphologically distinguished into smooth muscle cells and neuron cells. Based 
on these findings, ID3 maintains cells in a non-committed state by inhibiting the 
repression of pluripotency factors by TCF3. Furthermore we also recently reported 
that ID3 overexpression increased endothelial cell neovascularization, resistance 
to apoptosis, cell migration, and increased size of endothelial spheroids. In vivo, 
we reported that ID3 expression is higher in pulmonary vascular lesions. Our 
studies have also shown ID3 protein and oxidative damage highly expressed in 
benign and malignant cardiovascular tissues in patients (Das & Felty, 2014). In this 
study, we have elucidated the role of ID3 and ID3 candidate target genes in 
vascular-intimal lesions with the specific focus on how ID3 may play a critical role 
in regulating various genes and signaling pathways that are involved in cell 
adhesion, extracellular matrix proteolysis, & cell growth which predisposes the 
vessel to vascular dysfunction. A better understanding of how vascular-intimal 
lesions depend on ID3 regulation may open up novel approaches for both 
prevention & treatment of diseases these intimal-lesions manifest from.   
Materials & Methods  
Identification of microarray datasets & analysis. Our study was based on 
multiple studies carried out and deposited in NCBI Gene Express Omnibus (GEO), 
a public functional genomics data repository supporting MIAME-compliant data 
submissions in which both sequence-based and array data are accepted. Datasets 
were compiled on vascular diseases and respectively divided into blood & tissue 
studies. The following tables represents information on data collected & accessible 
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demographics of individual datasets. Note not all datasets are represented in the 
tables. Figure 3.1 represents a flow chart of our current study. 
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Table 4.1 NCBI GEO datasets represented in study. Table is divided into two cohorts: blood and tissue 
samples.
 
Blood studies 
 
 
Table 4.2.1 Characteristics of peripheral arterial disease dataset. 
 
 
Table 4.2.2 Characteristics of infantile hemangioma dataset. 
 
Characteristics Samples
Cases (n = 19) Controls (n = 18)
Age, years 69.57 ± 9.18 66.88 ± 9.44
Men, % 13 (68%) 13 (72%)
Ever smoker, % 17 (89%) 12 (66%)
BMI, kg⋅ m-2 28.53 ± 5.25 30.6 ± 5.99
Systolic BP, mm Hg 139.2 ± 23.27 132.4 ± 20.1
Diastolic BP, mm Hg 74.2 ± 11.66 80.1 ± 12.3
HDL cholesterol, mg/dl 44.12 ± 8.59 49.7 ± 15
Hypertension, % 17 (89.4%) 13 (72%)
Diabetes, % 5 (26%) 4 (22%)
Lipid-lowering medication, % 11 (57%) 12(66%)
Ankle-brachial index 0.48 ± 0.20 1.12 ± 0.07
WBC count, µL 8.03 ± 2.34 7.26 ± 1.10
Values are expressed as either 
'mean ± standard deviation' or 
as 'n (%)'
Patient	ID Lesions Age	at	time	of	resection Location	&	Size Comments
1 hemcEC-1 8	months 1.8	x	0.8	cm,	right	eyelid Normal	karyotype*
4 hemEC-4 3	months 3	x	3,	right	flank
5 hemEC-5 4	months 5	mm,	lower	abdomen Multiple	hemangiomas
8 heomaEC-8B 2	years B	-	ankle Normal	karyotype*,	multiple	
heomaEC-8C C	-	knee hemanigoendothelioma	lesions	of	variable	size,	new	lesions	still	appearing	at	2	years
heomaEC-8F F	-	right	foot
heomaEC-8G G	-	inner	thigh
10 hemEC-10 2	years 4	cm,	forehead
12 hemEC-12 4	months 1.5	cm,	left	cheek
13 hemEC-13 9	months 3	cm,	left	upper	eyelid Other	hemangiomas	on	neck	and	labia
17 hemEC-17A 10	months A.	3	cm,	scalp
hemEC-17B B.	3.5	x	4	cm,	forehead
20 8	months 8	months 2.5	cm,	neck Multiple	hemangiomas
21 9	months 9	months 6.5	x	5.5	cm,	scalp Other	hemangiomas	on	right	ear	and	forehead
*Endothelial	cells	from	these	patients	showed	a	normal	(46,	XX)	karyotype
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Table 4.2.3 Characteristics of atherosclerosis dataset. 
  
Table 4.2.4 Characteristics of atherosclerosis dataset. 
 
 
Table 4.2.5 Characteristics of atherosclerosis dataset.  
Homozygous FH Heterozygous FH Controls
Gender Female (n=6) Female (n=5) Female (n=16)
Male (n=20) Male (n=3) Male (n=10)
Age (years) 30.2 ± 11.1 28.8 ± 7.5 33.8 ± 11.2
LDL (mg/dl) 413.82 ± 92.33 (***)  220.64 ± 27.81 (***) 107.03 ± 17.78
HDL (mg/dl)  60.33 ± 8.09 54.17 ± 3.71 61.17 ± 6.60
Triglycerides (mg/dl)  141.31 ± 39.89  233.61 ± 132.80 107.63 ± 33.04
Lp(a) (mg/dl) 676.67 ± 347.06 442.73 ± 420.11 187.53 ± 153.59
Leukocytes (Gpt/l) 7.64 ± 0.95 5.45 ± 0.57 6.38 ± 0.8
Thrombocytes (Gpt/l) 253.12 ± 22.2 277.39 ± 37.51 258.12 ± 21.97
Values are means ± SD. FH, familial hypercholesterolemia; Gpt, Giga particles; Tpt, Terra particles.
Variable Africian American White Africian American White
CAC (coronary artery calcification) CAC < 10 CAC < 10 CAC >100 CAC > 100
n (number of patients) 17 41 13 26
Gender (male or female) female female female female
Age (years)  64.1  ±  7.7 62.9  ± 6.8 68.3  ± 8.5 69.0 ± 6.5
Body mass index (kg/m2*) 32.0  ±  6.4 25.5 ± 4.2 30.9 ± 7.1 27.4 ±  4.6
Systolic BP (mmHg)  119.1 ± 17.3  114.4 ± 18.7  130.6 ±  18.2  130.0 ±  22.6
Diastolic BP (mmHg)  68.6 ± 7.8  65.9 ± 11.1  71.4 ±  9.5  67.1  ±  8.7
Total cholesterol (mg/dl)  191.8 ± 32.4 197.5 ± 31.0  199.7   29.7 204.0   37.0
LDL cholesterol (mg/dl) 113.5 ±  27.7 110.2 ± 27.5 122.6   30.4 119.0   39.1
HDL cholesterol (mg/dl) 61.6   13.1 65.0   15.6 61.3   13.5 59.1   12.6
Triglycerides (mg/dl*§)  83.7   32.8 111.3   67.5  78.6   29.8  129.2   72.3
Fasting glucose (mg/dl) 91.5   8.0 89.7   8.5 90.6   7.5  91.0   8.7
HOMA insulin resistance 0.92   0.45 0.74   0.39 1.04   0.55  1.06   0.70
Insulin (uIU/ml) 4.4   2.0  3.6   1.8  4.8   2.4  4.9   3.1
Current smoker (%) 23.5 37.5 53.8 48
Lipid-lowering medication use (%) 5.8 15.3 38.4 52
Antihypertension medication use (%) 47 25.6 53.8 48
*P<0.05 comparing African American with white among women with coronary artery calcification (CAC) < 10
§P <0.05 comparing African American with white among women with CAC > 100
Baseline characteristics
Atherosclerotic patients (n=18) Control patients (n=13)
Age (years)  55.8 ± 7.9 52.2 ± 7.2
Male sex-no (%)  8 (44.4) 5 (38.5)
Body mass index (BMI) 25.2 ± 3.5  27.4 ± 3.5
Body surface area (BSA) 1.90 ± 0.21 1.97 ± 0.25
Family history of CAD – no. (%) 14 (77.8) 6 (46.2)
Current smoker – no. (%)  4 (22.2) 4 (30.8)
Ex smoker – no. (%)  7 (38.9)  4 (30.8)
Beta-blockers – no. (%) 15 (83.3)  10 (76.9)
Statins – no. (%) 18 (100)  13 (100)
Aspirin – no. (%) 18 (100)  13 (100)
Calcium antagonists – no. (%)  6 (33.3) 2 (16.4)
Nitrates – no. (%)  8 (44.4) 4 (30.8)
ACE-inhibitors/ARBs – no. (%)  8 (44.4)  7 (53.8)
Diuretics – no. (%) 4 (22.2) 4 (30.8)
C-reactive protein. – mg/dl 1.0 [1.0; 1.4] 1.1 [1.0; 1.7]
Troponin T – ng/ml <0.03  <0.03
Glucose – mmol/l  5.5 ± 1.7 5.7 ± 0.6
Triglycerides – mmol/l 1.17 ± 0.90 0.90 ± 0.63
Lipoprotein (a) – mg/dl  343 [63, 569] 90 [49; 163]
LDL-cholesterol – mmol/l  2.20 ± 0.79 1.87 ± 0.53
HDL-cholesterol – mmol/l 1.39 ± 0.46  0.90 ± 0.63
1) Patients with triple-vessel coronary artery disease and control patients 
did not show differences in clinical characteristics except for lipoprotein 
2) CAD = coronary artery disease
ARB = Angiotensin receptor blockers
ACE = angiotensin converting enyzme
⁎ Data expressed as median [1. quartile, 3. quartile]
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Tissue Studies  
 
Table 4.2.6 Characteristics of infantile hemangioma dataset.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: AVM, arteriovenous malformation; E, epistaxis; T,  
Telangiectasia; P, pulmonary AVM; C, cerebral AVM;  
G, gastrointestinal telangiectasia/gastrointestinal bleeding; H,  
Hepatic AVM; F, family history. M, male; F, female. 
 
Table 4.2.7 Characteristics of arteriovenous malformation dataset. 
Patient ID Age Gender Position Previous treatment Pathology
1 2 months 15 days Female Left axilla NO IH
2 2 months 13 days Female Right posterior neck Oral propranolol IH
3 1 year Female Abdomen Sclerotherapy IH
4 8 months Female Right thoracic wall Sclerotherapy IH
5 3 months Male Thoracic wall NO IH
Family No. Age Sex Phenotype
9 49 M E,T,P,G,F
9 53 F E,T,F
13 54 F E,T,P,G,F
13 30 F E,T,P,F
15 47 F E,T,G,F
15 38 M E,T,P,F
15 40 F E,T,F
24 40 F E,T,F
24 46 F E,T,P,G,F
37 51 M E,T,P,F
38 37 F E,T,F
49 47 F E,T,F
61 49 F E,T,F
65 35 F T,P,F
87 38 M T,P,F
92 44 M E,T,P
93 37 M E,T,F
94 30 M E,T,F
96 46 M E,T,P,F
8 55 M E,T,F
8 28 M E,T,F
18 43 M E,T,F
18 44 F E,T,P,F
18 41 M E,T,F
20 47 M E,T
42 32 F E,T,F
43 38 F E,T,F
43 36 F T,F
46 39 M E,T,F
47 40 F E,T,F
56 44 F E,T,F
57 34 M E,T,F
57 32 F T,F
67 24 F E,T,F
67 31 M E,T,F
69 39 M E,T,F
71 44 F E,T,F
82 48 M E,T,F
88 56 F E,T,G,F
88 50 M E,T,F
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Table 4.2.8 Characteristics of idiopathic pulmonary arterial hypertension dataset. 
Patient ID Gender (Age) Smoking Skin disease Autoantibody FVC FEV-1 DLCO (%)
FVC% / DLCO 
%
Mean PAP
(pack years) (type) (%) (%) (mmHg)
1 M 56.8 0 limited Th/To 40 48 34 1.18 18
3 F 57.8 10 limited centromere 88 85 38 2.32 51
4 F 51.3 10 diffuse n/a 34 43 22 1.55 30
5 F 39.3 0 diffuse Scl-70 24 31 31 1.55 22
6 M 59.0 40 n/a centromere 80 80 24 3.33 47
7 M 46.3 0 limited centromere 76 80 40 1.9 48
8 F 26.5 0 sine U11/U12 RNP 28 33 39 0.71 13
9 F 41.8 0 limited centromere 61 69 34 1.79 62
10 F 56.4 60 limited Th/To 64 34 29 2.2 42
11 M 45.3 0 diffuse Scl-70 30 34 23 1.3 23
13 M 42.5 8 diffuse U1 RNP 36 45 31 1.16 50
14 F 34.6 0 diffuse U11/U12 RNP 28 33 32 0.88 n/a
15 F 47.7 1 diffuse Scl-70 18 17 n/a n/a 14
16 F 36.8 7 limited Th/To 85 91 83 1.02 60
17 F 56.7 0 limited centromere 74 74 30 2.47 52
18 F 42.3 15 limited Scl-70 46 56 14 3.28 24
19 F 37.0 0 diffuse n/a 18 21 n/a n/a 26
21 F 56.2 55 n/a n/a 41 29 25 1.64 43
22 M 60.0 0 diffuse Scl-70 60 70 36 1.67 48
23 F 51.7 39 limited n/a 36 44 20 1.8 22
24 M 45.1 0 n/a n/a 26 28 30 0.87 23
25 F 51.8 12 diffuse n/a 23 25 n/a n/a 20
26 M 57.5 0 diffuse n/a 33 46 26 1.27 24
27 F 41.6 5 diffuse U11/U12 RNP 42 44 31 1.35 15
28 M 58.2 30 diffuse RNA polymerase 63 77 16 3.93 38
29 F 60.1 0 limited Scl-70 61 70 20 3.05 23
30 F 58.8 0 n/a n/a 39 50 14 2.79 19
32 F 63.8 0 limited centromere 59 70 n/a n/a 44
33 F 63.5 0 limited RNA polymerase 82 95 25 3.28 31
35 M 54.2 0 n/a n/a 40 47 n/a n/a 38
36 M 49.0 30 diffuse U11/U12 RNP 76 67 n/a n/a 43
37 M 47.2 0 diffuse n/a 52 58 20 2.6 35
38 F 49.0 30 limited n/a 26 32 19 1.37 21
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Figure 4.1 Flow chart summarizing the steps in this study. 
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Computational identification of ID3 and ID3 candidate target genes. 
Respectively each dataset has a different number of genes signifying the genome 
(~13,000 – 35,000). To compare the data, the identification of commonly 
expressed genes across all studies in both blood and tissue was first established. 
A total number of 3665 genes were commonly represented in each study. In order 
to remove systematic variation in the microarray experiments which affects the 
measured gene expression levels, raw data was discretized using the function: (IF 
(Sample>Average+0.5*Standard Deviation, 2, IF (Sample>Average-
0.5*Standard*, 1, 0))). Expression levels were signified as 0 (under/low-
expression), 1 (normal expression), & 2 (overexpression). To classify ID3 
candidate target genes, a pearson correlation test was conducted. This is a 
measure of linear correlation between two variables: X & Y and is represented by 
a value between  -1 and 1, where -1 is a total negative correlation, 0 is no 
correlation, & 1 is a total positive correlation. Additionally the interquartile range 
(IQR), which is a measure of variability, based on dividing a set of data in quartiles 
(Q1 - 25th percentile, Q2- 50th percentile, Q3 – 75th percentile, and Q4 – 100th 
percentile) was calculated. Genes that were measured between Q3 (75th 
percentile) & Q4 (100th percentile) were identified as best correlated with ID3. 
Additionally an independent t-test, which compares the means of two independent 
groups in order to determine whether there is statistical evidence that the 
associated population means are significantly different was used to test statistical 
differences between means of two groups (disease and control). Our common 
gene list (3665) was used during our t-test and significance value was considered 
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at p≤ 0.05 and IQR was determined. Genes measured in the Q1 (25th percentile) 
was represented as significant. In order to generate the conclusive list of ID3 
candidate targets, genes that were mutually expressed in Q3 and Q4 of the 
Pearson correlation analysis and Q1 of the t-test were included as candidate 
targets. This method was done separately for whole blood and tissue studies. 
Furthermore the top 10 most significant ID3 targets in both blood and tissue 
samples were also identified.  
Bayesian analysis & network. Due to the development of biomedical data in 
biology & medicine with vast number of variables, Bayesian networks have been 
successfully used in developing effective algorithms that scale up to datasets 
connecting numbers of variables in learning high quality predictive models from 
genomic data (Yoo et al. 2002; Yoo and Cooper, 2004). A Bayesian network is a 
directed acyclic graph in which each node represents a variable and each arc 
represents probabilistic influence. In Bayesian Networks, each arc is interpreted 
as a direct influence between a parent node (variable) and a child node, relative to 
the other nodes in the network. Structure of Bayesian network with respect to a 
decomposable score such as BIC, BDe, or AIC becomes infeasible as the number 
of variables increases. A much simpler algorithm for finding the globally optimal 
Bayesian network structure without any structural limitations is used with n<33 
which is also known as Bene. The approach is broken down into five logical steps: 
Step 1. Compute the local scores for all n2n − 1 different (variable, variable set) – 
pairs; Step 2. Using the local scores, find the best parents for all n2n−1 (variable, 
parent candidate set)-pairs; Step 3. Find the best sink for all 2n variable sets; and 
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Step 4. Using the results from Step 3, find a best ordering of the variables. Step 5. 
Find a best network using results computed in Steps 2 and 4 (Silander & 
Myllymak). 
Genie. Genie Modular is a graphical user interface to SMILE (Structural Modeling, 
Interface, & Learning Engine) is a fully platform independent library of C++ classes 
applying decision-theoretic models & graphical probabilistic, such as Bayesian 
networks, influence diagrams, and structural equation models. A graph 
demonstrates much about the structure of a probabilistic domain but not much 
about its numerical properties. These are encoded in conditional probability 
distribution matrices (equivalent to the factors in the factorized form), called 
conditional probability tables (CPTs) that are associated with the nodes. There will 
always be nodes in the network with no predecessors. These nodes are 
categorized by their prior marginal probability distribution. Any probability in the 
joint probability distribution can be determined from these explicitly represented 
prior and conditional probabilities. 
Gene Ontology & Pathway Analysis. To understand the functions of the gene 
list we applied two gene ontology tools: Princeton University Lewis-Sigler Institute 
for Integrative Genomics Gene Ontology (GO) Tools (http://go.princeton.edu/), & 
STRING database version 10 (http://string-db.org/). All tools provide a 
knowledgebase of functional annotation tools for investigators to understand 
functional meaning (biological, molecular) behind various sizes of gene lists. 
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Comparative Toxicogenomic Database (CTD) Analysis. CTD is a publicly 
available database that aims to advance understanding about how environmental 
exposures affect human health (Davis et al. 2016). The database provides curated 
information about chemical–gene/protein interactions, chemical–disease and 
gene–disease relationships. The data are integrated with functional and pathway 
data to support in development of hypotheses about the mechanisms essential 
environmentally predisposed diseases. To understand the association between 
endocrine disrupting chemicals (PCBs and BPA) & ID3/ID3 target genes, CTD was 
used to investigate the association between PCB/BPA associated genes & ID3/ID3 
target genes identified in both blood and tissue respectively. Furthermore 
overlapping blood-tissue ID3 target genes and their association with both PCBs 
and BPA was also examined. Results were summarized in venn diagrams and final 
lists was provided for each.  
Results 
Gene expression of ID3 & ID3 candidate targets in blood & tissue studies. 
We identified ID3 & ID3 candidate target genes in all blood studies and tissue 
studies. Table 4.3 and 4.5 shows a listing of ID3 and ID3 candidate target genes.  
In blood, 217-candidate target genes were identified and in tissue 134-candidate 
target genes were identified. Top 10 most significant ID3 target genes were 
identified in blood & tissue studies summarized in tables 4.4 & 4.6. Top 10 most 
significant ID3 targets in blood includes: COL1A2, COL6A1, CYP2C18, DIRAS3, 
DLG2, DZIP1, GCLM, GDF11, GRP, and KNG1. The top 10 most significant ID3 
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targets in tissue includes: ACLY, ACP1, ARPC4, ATP5D, CAMK1, CDKN2B, 
COPE, CYC1, EIF4EBP2, and MCRS1. 
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Table 4.3 ID3 and ID3 candidate target genes identified in blood studies. 
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Table 4.4 Top 10 most significant ID3 candidate target genes in blood.  
 
 
Gene Symbol Entrez Gene Title 
COL1A2 collagen type I alpha 2 chain (COL1A2)
COL6A1 collagen type VI alpha 1 chain (COL6A1)
CYP2C18 cytochrome P450 family 2 subfamily C member 18 (CYP2C18)
DIRAS3 DIRAS family GTPase 3 (DIRAS3)
DLG2 discs large MAGUK scaffold protein 2 (DLG2)
DZIP1 DAZ interacting zinc finger protein 1 (DZIP1)
GCLM glutamate-cysteine ligase modifier subunit (GCLM)
GDF11 growth differentiation factor 11 (GDF11)
GRP gastrin releasing peptide (GRP)
KNG1 kininogen 1 (KNG1)
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Table 4.5 ID3 and ID3 candidate target genes in tissue studies. 
 
 
Table 4.6 Top 10 most significant ID3 candidate target genes in tissue. 
Gene expression in blood versus tissue studies. Overlapping ID3 & ID3 
candidate target genes were identified between blood & tissue samples. Genes 
include: ABCB6, ACP1, BYSL, CAD, CDH15, DCBLD2, DHRS3, DNMT1, ID3, 
MCM4, and NDUFA7 as shown in Table 4.7 & Figure 4.3 Furthermore we 
demonstrated the results in both Bene and Genie models (Figure 4.4 & 4.5.1 – 
4.5.4) illustrating a fully connected structure and probability distribution of gene 
expression. 
Gene Symbol Entrez Gene Title 
ACLY ATP citrate lyase (ACLY)
ACP1 acid phosphatase 1, soluble (ACP1)
ARPC4 actin related protein 2/3 complex subunit 4 (ARPC4)
ATP5D ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit (ATP5D)
CAMK1 calcium/calmodulin dependent protein kinase I (CAMK1)
CDKN2B cyclin dependent kinase inhibitor 2B (CDKN2B)
COPE coatomer protein complex subunit epsilon (COPE)
CYC1 cytochrome c1 (CYC1)
EIF4EBP2 eukaryotic translation initiation factor 4E binding protein 2 (EIF4EBP2)
MCRS1 microspherule protein 1 (MCRS1)
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           Table 4.7 ID3 and common candidate target genes between blood and tissue studies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Venn diagram illustration summarizes ID3 & ID3 candidate target genes. Left circle represent 
genes in blood studies (134), right circle represent genes in tissue studies (217), & the middle intersection of 
the two circles represent the shared genes between both blood & tissue studies (11). 
 
 
Gene Symbol Entrez Gene Title
ABCB6 ATP binding cassette subfamily B member 6 (Langereis blood group) (ABCB6)
ACP1 acid phosphatase 1, soluble (ACP1)
BYSL bystin like (BYSL)
CAD carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD)
CDH15 cadherin 15 (CDH15)
DCBLD2 discoidin, CUB and LCCL domain containing 2 (DCBLD2)
DHRS3 dehydrogenase/reductase 3 (DHRS3)
DNMT1 DNA methyltransferase 1 (DNMT1)
ID3 inhibitor of DNA binding 3, HLH protein (ID3)
MCM4 minichromosome maintenance complex component 4 (MCM4)
NDUFA7 NADH: ubiquinone oxidoreductase subunit A7 (NDUFA7)
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Figure 4.3 Representation of ID3 and overlapping ID3-candidate target genes in both blood and 
tissue samples. Bene, a method for finding the globally optimal Bayesian network produced a fully 
connected structure. 
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Figure 4.4.1 Best fit model based on Genie Modeler with overlapping ID3 & ID3-candidate target 
genes. 
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Figure 4.4.2 Representation of ID3 & ID3-candidate targets in vascular state. Left panel represents 
model in disease state and right panel represents model in non-disease state. 
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Figure 4.4.3 Representation of ID3 & ID3-candidate targets in location of vascular disease. Left panel 
represents model in blood & right panel represents model in tissue.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 135 
 
 
Figure 4.4.4 Representation of models based on expression of ID3. Left panel summarizes ID3 low-
expression, middle panel represents ID3 normal-expression, & the right panel summarizes ID3-high 
expression.  
Gene expression of ID3 & ID3 candidate target genes in specific vascular 
diseases in blood & tissue. Our investigation indicated the expression of ID3 & 
ID3 candidate target genes within each vascular disease. Figure 4.6.1 illustrates 
the diverse number of candidate targets and overlapping genes between each 
disease in blood studies. Number of candidate targets genes (n) include: 
atherosclerosis (357); arteriovenous malformation (36); peripheral arterial disease 
(190); proliferative diabetic retinopathy (403); infantile hemangioma (84); idiopathic 
pulmonary arterial hypertension (75); & Lymphangioleiomyomatosis (363).The 
analysis also identified ID3 & ID3 candidate target genes within each vascular 
disease in tissue studies. Figure 4.6.2 illustrates the diverse number of candidate 
targets and overlapping genes between each disease. Number of candidate 
targets genes (n) include: arteriovenous malformation (277); proliferative diabetic 
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retinopathy (403); infantile hemangioma (98); idiopathic pulmonary arterial 
hypertension (973); & Lymphangioleiomyomatosis (231). 
 
Figure 4.5.1 Venn diagram illustration summarizes ID3 & ID3 candidate target genes in vascular 
diseases in blood studies. Each shape represents a different disease that includes blood samples. Diseases 
include: IH (Infantile Hemangioma), PAD (peripheral arterial disease), AVM (arteriovenous malformation), 
LAM (Lymphangioleiomyomatosis), IPAH (idiopathic pulmonary arterial hypertension), & AS (atherosclerosis). 
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Figure 4.5.2 Venn diagram summarizes ID3 & ID3 candidate target genes in specific diseases in tissue 
studies. Each ovular shape represents a vascular disease. Diseases in tissue studies include: IH (Infantile 
Hemangioma), AVM (arteriovenous malformation), LAM (Lymphangioleiomyomatosis), PDR (Proliferative 
Diabetic Retinopathy), & IPAH (Idiopathic pulmonary arterial hypertension). 
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ID3 & ID3 gene-associated biological processes 
ID3 and ID3 candidate target genes in blood. In order to understand the roles 
of these genes in functional processes a gene ontology approach was used via the 
Princeton University Lewis-Sigler Institute for Integrative Genomics Gene 
Ontology (GO) Tool to demonstrate the processes in which ID3 & ID3 candidate 
target genes in blood were represented. The genes were demonstrated in 122 
biological processes and are represented in Table 4.8.
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Table 4.8 Demonstration of biological processes that ID3 & ID3 target genes are involved with in blood. 
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ID3 and ID3 candidate target genes in tissue. In order to understand the roles 
of these genes in functional processes gene ontology methodology was used to 
demonstrate the processes in which ID3 & ID3 candidate target genes in tissue 
were overrepresented. Candidate target genes in tissue were overrepresented in 
89 biological processes.  
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Table 4.9 Biological processes that ID3 & ID3 candidate target genes in tissue.  
 
 
ID3 & ID3 gene-associated signaling pathways 
ID3 and ID3 candidate target genes in blood. In order to understand the 
potential relationships among the genes in the most over-represented processes 
STRING, a database of predicted & identified protein-protein interactions was used 
to show direct (physical) and indirect (functional) associations. ID3 & ID3 candidate 
target genes in blood (134) was matched to the database and generated network 
maps for the genes involved in over-represented processes. We show that ID3 and 
ID3 candidate target genes in blood are involved in 5 pathways (Arrhythmogenic 
right ventricular-cardiomyopathy, Neuro-active ligand-receptor interaction, focal 
adhesion, ECM-receptor interaction, & hypertrophic cardiomyopathy as shown in 
Table 4.10 Interestingly two of the pathways represented ID3 as matching proteins. 
Focal adhesion pathway includes proteins: ACTN1, COL1A2, COL3A1, COL6A1, 
CTNNB1, IBSP, ID3, ITGA8, and MYL2. ECM-receptor interaction includes 
proteins: COL1A2, COL3A1, COL6A1, IBSP, ID3, and ITGA8. Figure 4.7.1 and 
4.7.2 demonstrate both networks. Furthermore we also represented the biological 
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processes these genes (134) are signified as seen in Table 4.11. Overall 119 
biological processes are over-represented via ID3 & ID3 candidate genes in blood.  
 
Table 4.10 Demonstrated pathways of ID3 and ID3 candidate targets genes in blood.
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Figure 4.6.1 Network demonstrated from STRING database of ID3-involved pathway in Extra Cellular 
Matrix Receptor (ECM) interaction. Genes (6) highlighted in red are involved in the pathway: COL1A2, 
COL3A1, COL6A1, IBSP, ID3, and ITGAB   
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Figure 4.6.2 Network demonstrated from STRING database of ID3-involved pathway in focal 
adhesion. Genes (9) highlighted in red are involved in the pathway: ACTN1, COL6A1, COL6A2, COL3A1, 
CTNNB1, IBSP, ID3, ITGAB, and MYL2.
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Table 4.11 Biological processes represented through STRING database of ID3 & ID3-candidate targets 
proteins in blood. Table represents 119 biological processes.   
 
ID3 and ID3 candidate target genes in tissue. Furthermore we also used 
STRING to investigate the potential relationships among ID3 & ID3 candidate 
target genes in tissue (217). These genes demonstrate to be involved in 20 
pathways as shown in Table 4.12. Additionally two of the pathways represented 
have a role in vascular diseases. Oxidative phosphorylation pathway included 
proteins:  ATP5D, ATP5H, ATP6V0B, ATP6V0D1, ATP6V1B2, COX5A, COX7C, 
COX8A, CYC1, ID3, NDUFA1, NDUFA7, NDUFS4, NDUFV1, and NDUFV2. Cell 
cycle pathway includes: ANAPC10, ATM, CDKN2B, E2F5, MCM3, and MCM4. 
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Figures 4.8.1 and 4.8.2 represent both pathways. We also show the biological 
processes in which these genes (217) are over-represented in. A total of 116 
processes are shown in Table 4.13. 
 
 
       Table 4.12 Demonstrated pathways of ID3 & ID3 candidate target proteins in tissue. 
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Figure 4.7.1 Network demonstrated from STRING database of ID3 candidate targets involved in the 
oxidative phosphorylation pathway. Proteins involved in the pathway: ATP5D, ATP5H, ATP6V0B, 
ATP6V0D1, ATP6V1B2, COX5A, COX7C, COX8A, CYC1, NDUFA1, NDUFA7, NDUFS4, NDUFV1, and 
NDUFV2. 
 
Figure 4.7.2 Network demonstrated from STRING database of ID3 candidate targets involved in the cell 
cycle pathway. Proteins include: ANAPC10, ATM, CDKN2B, E2F5, MCM3, and MCM4.
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Table 4.13 Biological processes of ID3 and ID3 candidate target genes in tissue. Gene ontology (GO) 
shown via STRING database demonstrate 116 biological processes. 
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ID3 & ID3 candidate target genes & EDC-associated genes. Comparative 
Toxicogenomic Database examination yielded various results.  When comparing 
ID3 candidate target genes in blood (134) with PCB associated genes (648) results 
demonstrated 12 genes which include: AEBP1, APOH, CHEK1, DNMT1, DTYMK, 
FKBP4, GFRA1, HIST1H4C, ID3, IL6, LIFR, and MTTP (Figure 4.9.1 & Table 
4.15.1).  Furthermore, when comparing ID3 candidate target genes in tissue (217) 
with PCB associated genes (648) results showed 13 genes including: ACOX1, 
ACTR2, ALDOC, CDK2AP2, CSF3R, CTSZ, DNMT1, GPI, HSP90AB1, ID3, ILF2, 
ITGB5, LY96 (Figure 4.9.2 & Table 4.15.2).  Additionally, we also investigated two 
specific PCB congeners (PCB153 and PCB180) and examined their associated 
genes with ID3/ID3 candidate target genes. ID3 candidate target genes in blood 
(134) and PCB153-associated genes (2016) resulted in 19 genes including: CCL7, 
CTNNB1, DCX, DLG2, DTYMK, DUSP14, FNBP1, GRIN2B, HMGB3, HNF4G, 
HS3ST1, HTR4, IFIH1, IGFBP2, IL6, LIFR, MCM4, MMP11, and NDUFA7 (Figure 
4.9.4 & Table 4.15.4).  ID3 candidate target genes in tissue (217) and PCB153-
associated genes (2016) resulted in 24 genes: ABCA1, AOX1, APOD, ASGR2, 
ATM, BAX, COG7, EEF2, ELF4, GOT1, GPC5, GPX1, HIST1H1B, HMGCR, 
HTATIP2, IDH2, IL2RA, MAPK1, MCM3, MCM4, MGST3, MTM1, MVK, NDUFA7 
(Figure 4.9.5 & Table 4.15.5). When comparing ID3 candidate target genes in 
blood (134) with PCB180-assciated genes (1876) results yielded 20 genes 
including: ACTN1, ARID5B, CACNG3, CCL7, CHEK1, DCX, DLG2, DUSP14, 
FBLN5, FNBP1, GRIN2B, HDAC4, HMGB3, HNF4G, HS3ST1, HTR4, IFIH1, IL6, 
MCM4, and NDUFA7 (Figure 4.9.7 & Table 4.15.7). ID3 candidate target genes in 
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tissue (217) vs. PCB180-associated gens (1876) resulted in 18 genes:  APOD, 
ATM, BAX, COG7, ELF4, GPC5, HIBCH, HSP90AB1, HTR2A, IL2RA, LGALS1, 
LGALS3BP, MAPK1, MCM3, MCM4, MGST3, MTM1, and NDUFA7 (Figure 4.9.8 
& Table 4.15.8).  Lastly we also demonstrated BPA-associated genes (19169) with 
ID3 candidate targets in both blood and tissue respectively. These results indicated 
126 genes in blood and 202 genes in tissue further demonstrated in Figures 4.10.1 
& 4.10.2 and Tables 4.16.1 & 4.16.2. 
 
Figure 4.8.1 Venn diagram illustrating ID3 candidate target genes in blood with PCBs. ID3 candidate 
target genes (134), PCB associated genes (648), and overlapping genes (12).  
 
Table 4.14.1 ID3 candidate target genes in blood associated with polychlorinated biphenyls 
(PCBs). 
Associated ID3 Target Genes in blood with PCBs 
AEBP1
APOH
CHEK1
DNMT1
DTYMK
FKBP4
GFRA1
HIST1H4C
ID3
IL6
LIFR
MTTP
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Figure 4.8.2 Venn diagram illustrating ID3 candidate target genes in tissue with PCBs. ID3 candidate 
target genes (217), PCB associated genes (648), and overlapping genes (13) 
 
 
Table 4.14.2 ID3 candidate target genes in tissue associated with polychlorinated biphenyls (PCBs). 
 
Associated ID3 Target Genes in tissue with PCBs 
ACOX1
ACTR2
ALDOC
CDK2AP2
CSF3R
CTSZ
DNMT1
GPI
HSP90AB1
ID3
ILF2
ITGB5
LY96
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Figure 4.8.3 Venn diagram summarizing overlapping ID3 candidate target genes in blood-tissue with 
PCBs. ID3 candidate target genes (11), PCB associated genes (648), and overlapping genes (2) 
 
 
 
Table 4.14.3 Overlapping ID3 candidate target genes in blood-tissue associated with polychlorinated 
biphenyls (PCBs). 
 
Figure 4.8.4 Venn diagram summarizing ID3 candidate target genes in blood with PCB153. ID3 
candidate target genes (134), PCB153 associated genes (2016), and overlapping genes (19) 
 
Overlapping ID3 Candidate Target Genes
Genes in blood-tissue with PCBs 
DNMT1
ID3
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Figure 4.14.4 ID3 candidate target genes in blood associated with polychlorinated biphenyl 153 
(PCB153). 
 
 
 
 
Figure 4.8.5 Venn diagram summarizing ID3 candidate target genes in tissue with PCB153. ID3 
candidate target genes (217), PCB153 associated genes (2016), and overlapping genes (24). 
 
Associated ID3 Candidate Target Genes in blood with PCB153
CCL7
CTNNB1
DCX
DLG2
DTYMK
DUSP14
FNBP1
GRIN2B
HMGB3
HNF4G
HS3ST1
HTR4
IFIH1
IGFBP2
IL6
LIFR
MCM4
MMP11
NDUFA7
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Figure 4.14.5 ID3 target genes in tissue associated with polychlorinated biphenyl 153 (PCB153). 
Figure 4.8.6 Venn diagram summarizing ID3 candidate target genes in blood-tissue. ID3 candidate target 
genes (11), PCB153 associated genes (2016), and overlapping genes (2). 
 
 
Associated ID3 Candidate Target Genes in tissue with PCB153
ABCA1
AOX1
APOD
ASGR2
ATM
BAX
COG7
EEF2
ELF4
GOT1
GPC5
GPX1
HIST1H1B
HMGCR
HTATIP2
IDH2
IL2RA
MAPK1
MCM3
MCM4
MGST3
MTM1
MVK
NDUFA7
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Figure 4.14.6 ID3 target genes in blood-tissue associated with polychlorinated biphenyl 153 
(PCB153). 
 
Figure 4.8.7 Venn diagram summarizing ID3 target genes in blood with PCB180. ID3 candidate target 
genes (134), PCB180 associated genes (1876), and overlapping genes (20). 
 
 
Figure 4.14.7 ID3 candidate target genes in blood associated with polychlorinated biphenyl 180 
(PCB180). 
Overlapping ID3 Candidate Target Genes
 in blood-tissue with PCB153 
MCM4
NDUFA7
Associated ID3 Candidate Target Genes in blood with PCB180
ACTN1
ARID5B
CACNG3
CCL7
CHEK1
DCX
DLG2
DUSP14
FBLN5
FNBP1
GRIN2B
HDAC4
HMGB3
HNF4G
HS3ST1
HTR4
IFIH1
IL6
MCM4
NDUFA7
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Figure 4.8.8 Venn diagram summarizing ID3 candidate target genes in tissue with PCB180. ID3 
candidate target genes (217), PCB180 associated genes (1876), and overlapping genes (18).  
 
 
Figure 4.14.8 ID3 candidate target genes in tissue associated with polychlorinated biphenyl 180 
(PCB180). 
 
Figure 4.8.9 Venn diagram summarizing overlapping ID3 candidate target genes in blood-tissue with 
PCB180. ID3 candidate target genes (11), PCB180 associated genes (1876), and overlapping genes (2).  
 
Associated ID3 Candidate Target Genes in tissue with PCB180
APOD
ATM
BAX
COG7
ELF4
GPC5
HIBCH
HSP90AB1
HTR2A
IL2RA
LGALS1
LGALS3BP
MAPK1
MCM3
MCM4
MGST3
MTM1
NDUFA7
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Table 4.14.9 ID3 candidate target genes in blood-tissue associated with polychlorinated biphenyl 180 
(PCB180).  
 
 
Figure 4.9.1. Venn diagram summarizing ID3 candidate target genes in blood with BPA. ID3 candidate 
target genes (134), Bisphenol A associated genes (19169), and overlapping genes (126).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Overlapping ID3 Candidate Target
Genes in blood-tissue with PCB180 
MCM4
NDUFA7
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Table 4.15.1 ID3 candidate target genes in blood associated with BPA.  
 
Figure 4.9.2. Venn diagram summarizing ID3 candidate target genes in tissue with BPA. ID3 candidate 
target genes (217), Bisphenol A associated genes (19169), and overlapping genes (202) 
 
ABCA4 COL1A2 GLRA1
ABCB6 COL3A1 GPR135
ACIN1 COL6A1 GPR37L1
ACP1 COPB2 GRIA2
ACTA2 CREBBP GRIK5
ACTN1 CRYAA GRIN2B
ADAMTS3 CTGF GRP
AEBP1 CTH HDAC4
AGTR2 CTNNB1 HDDC2
ANKRD26 CTSF HMGB3
ANPEP CYP26A1 HMGCS2
APAF1 CYP4F11 HNF4G
APOF CYR61 HOXD3
APOH DAAM1 HS3ST1
ARID5B DAB2 HSPB2
ARSA DCX HTR4
ASB4 DHRS3 IBSP
ASNS DHRS7 ID3
ATP7B DIRAS3 IFIH1
AVPR2 DLG2 IGFBP2
BCAM DNAJC7 IL13RA2
BCL2L2 DNMT1 IL6
BYSL DOCK9 INHBB
C10ORF10 DRD1 ITGA8
CACNB4 DTYMK KCNH2
CACNG3 DUSP14 KCNJ4
CAD DYRK3 KCNK1
CALR DZIP1 KIF1A
CCL7 EEF1E1 KNG1
CCT8 ETS1 LGR5
CDH15 FBLN2 LIFR
CDH16 FBLN5 LMO3
CDH17 FBP2 MAN1A2
CDH2 FKBP4 MCM4
CDH6 FNBP1 MLLT10
CFDP1 FUT9 MMP11
CFTR GABRA2 MPP3
CH25H GAL MPP6
CHEK1 GAS8 MTTP
CKM GCLM MYL2
CNKSR2 GDF11 NDP
COL17A1 GFRA1 NDUFA7
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Table 4.15.2 ID3 candidate target genes in tissue associated with BPA.  
Discussion   
To our knowledge this is a novelty study approach investigating ID3 and ID3 
candidate target genes in vascular-intimal lesions. Our analysis intergrading both 
statistical & bioinformatics methods attempts to identify ID3 and ID3 candidate 
target genes alongside key gene networks that differentiate vascular disease 
subjects from non-disease subjects. We have used these approaches to elucidate 
a core set of genes in both blood & tissue that represent ID3 and potential targets. 
Interestingly 11 of these genes are mutually expressed in the two locations of 
ABCA1 BAX DCTN2 GLB1 LASP1 NDUFV1
ABCB6 BCAP31 DCTN5 GOLGA3 LGALS1 NDUFV2
ACLY BCAR3 DDB1 GOSR2 LGALS3BP NEDD8
ACOX1 BCAT2 DDN GOT1 LMAN1
ACP1 BCL7B DDO GPAA1 LMNA
ACTR1A BNIP3 DEGS1 GPC5 LRRC42
ACTR2 BYSL DHCR7 GPD1L LSM3
ADRM1 C4BPB DHRS3 GPI LY96
AGGF1 CAD DHX16 GPR39 M6PR
AHCTF1 CAMK1 DHX8 GPR4 MAPK1
AK2 CASK DNAJB6 GPX1 MAPK13
ALDH3B1 CCDC6 DNAJC8 GRIN2D MAPKAPK3
ALDOC CCNI DNASE2 H1F0 MAPRE1
ALPL CD2BP2 DNMT1 HAGH MCM3
ANAPC10 CD99 DPM2 HCLS1 MCM4
AOX1 CDH15 DYRK4 HERC4 MCRS1
AP2S1 CDK2AP2 E2F5 HESX1 MFGE8
API5 CDK5 EEF2 HIBCH MFSD5
APOD CDKN2B EIF2B1 HIST1H1B MGAT1
APRT CEBPG EIF4EBP2 HIST1H1D MGST3
ARCN1 CHMP2A EIF4G1 HMGCR MIF
ARF4 CLN3 EIF5A HSP90AB1 MPDU1
ARF5 CLPP ELAC2 HTATIP2 MPI
ARFGEF2 CLTB ENO1 HTR2A MPPE1
ARID3A COG7 EPHA1 ICA1 MR1
ARL1 COMMD4 EPRS ID3 MRPL12
ARPC1A COPE ERAL1 IDH2 MRPS12
ARPC4 COPS3 ERCC2 IDH3B MSN
ASGR2 COPS7A FAM20B IDH3G MTHFS
ASPHD1 COX5A FAM50A IFNGR2 MTM1
ATF6 COX7C FLAD1 IGFBP5 MYBPC2
ATM COX8A FLOT2 IL2RA MYO7A
ATOX1 CSF3R FRAT2 ILF2 NAGLU
ATP5D CSPG5 FXR2 IMP4 NAGPA
ATP5H CTNNBIP1 FZD2 ITGAM NCK1
ATP6V0B CTSZ G3BP2 ITGB5 NCSTN
ATP6V0D1 CYB561D2 GABRD IVD NDST1
ATP6V1B2 CYC1 GALK2 KIFAP3 NDUFA1
AXIN1 CYHR1 GATA2 KPNA4 NDUFA7
BAX DAP GBF1 KRT19 NDUFS4
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vascular diseases: blood & tissue. These genes whose involvement in various 
biological processes such as extracellular matrix, focal adhesion, & cell growth 
may help explain how ID3 signaling drives vascular dysfunction in the 
pathogenesis of these vascular diseases, in which vascular-intimal lesions 
manifest from. All mutually represented ID3 candidate target genes in both blood 
& tissue demonstrate known roles in vascular diseases forming a tight cluster that 
is largely centered on the regulation of these biological processes. 
The identification of ID3 & ID3 candidate target genes helped truncate our 
vast quantity of mutually expressed genes (3665) across all the data. In our 
analysis we identified ID3 and ID3 candidate target genes in blood (134) and tissue 
(217) studies. In blood, 5 pathways were overrepresented by these genes. 
Interestingly, 2 pathways contribute to vascular perturbation in the lesion: 
extracellular matrix-receptor interaction & focal adhesion. The extracellular matrix 
(ECM); which is a dynamic composite of various proteins that form structures 
connecting cells, provides an architectural framework within the network. Blood 
vessels are inflated by blood pressure and thus require ECM mechanisms with 
enough tensile strength and elasticity to resist rupture (Ponticos & Smith. 2014). 
Furthermore focal adhesion, a type of adhesive contact between the cell and 
extracellular matrix is essential for proliferation, cell migrations, and embryonic 
development (Eleniste & Bruzzaniti. 2012). Together both regulate & control 
cellular function through biochemical and mechanical signaling. Cells respond to 
the ECM by alternating their environment which becomes dysregulated in vascular 
diseases such as atherosclerosis, restenosis, and hypertension (Ponticos & Smith. 
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2013). Both components are important for maintaining vascular integrity and 
prevention of unfavorable vascular remodeling (Raines. 2000). Overrepresented 
genes in both pathways include COL1A2, COL3A1, COL6A1, IBSP, ID3, & ITGA8. 
Type I collagens COL1A1 and COL1A2 are part of the fibullar a-cellular component 
of basement membranes and connective tissue (Yurchenco, 2011). Most recently 
it was shown that the expression of pro-inflammatory genes such as TNF-α and 
MCP-1 was significantly up-regulated as well as the expression of the pro-
remodeling genes collagen type I, fibronectin and the metalloproteinase MMP-2 
and TIMP-1 (Zelko et al., 2016). Interestingly ID3 snp rs11574 was demonstrated 
to up-regulate MMP3 & down-regulate COL6A3 leading to the stimulation of 
atherogensis, which includes biological processes such as apoptosis, cell 
movement, cellular proliferation, immune trafficking, & adhesion (Doran et al., 
2010). Integrin binding sialoprotein protein (IBSP) is a major structural protein of 
the bone matrix. The expression of IBSP also significantly increased on collagen 
type I (7 fold), vitrovectin (5 fold), and laminin during a study where the role of ECM 
proteins in regulating the proliferation and osteogenic differentiation of bone 
marrow derived human mesenchymal stem cells (hMSCs) was examined 
(Matthews et al., 2012). In tissue, 20 pathways were overrepresented by ID3 
candidate target genes. Two pathways were identified as a contributing factor to 
vascular dysfunction: oxidative phosphorylation & cell cycle pathway. Oxidative 
phosphorylation, which is the metabolic pathway in which cells use enzymes to 
oxidize nutrients is essential in the pathogenesis of vascular disease. 
Overproduction of reactive oxygen species (ROS) under various pathophysiologic 
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conditions can trigger certain pathways that may lead to vascular inflammation 
causing vessel & plaque rupture (Madamanchi et al. 2005; Gao et al. 2008). 
Vascular smooth muscle cell proliferation is a key component in the healing 
process of vascular dysfunction. This process is facilitated by multiple growth 
factors and cytokines which share a common pathway in inducing cell proliferation: 
the cell cycle (Braun-Dullaeus et al. 1998; Charron et al. 2006). Key molecular 
events in atherogenesis such as phospholipids, endothelial cell activation, 
oxidative modification of lipoproteins, and macrophage activation/infiltration are 
facilitated by vascular oxidative stress and inhibited by endothelial nitric oxide 
(Förstermann et al., 2017). Furthermore angiogenesis in the 3D collagen gel was 
demonstrated recently to be regulated by the JAK/STAT3 pathway which involves 
alterations in vessel diameter, vessel length, and sprout number. The essential 
mechanism was that the JAK/STAT3 signaling pathway regulated angiogenesis by 
perturbations in numbers of angiogenesis-associated growth factors and by direct 
regulation of cell cycle (Xue et al., 2016). Furthermore the top 10 most significant 
ID3 candidate target genes in both blood and tissue were demonstrated. In blood 
these genes include: COL1A2, COL6A1, CYP2C18, DIRAS3, DLG2, DZIP1, 
GCLM, GDF11, GRP, and KNG1. In tissue these genes include: ACLY, ACP1, 
ARPC4, ATP5D, CAMK1, CDKN2B, COPE, CYC1, EIF4EBP2, and MCRS1. 
Additionally, genes including: ABCB6, ACP1, BYSL, CAD, CDH15, 
DCBLD2, DHRS3, DNMT1, ID3, MCM4, & NDUFA7 are represented both in blood 
& tissue data. In order to initially establish if these genes had an interaction within 
their network, a globally optimal Bayesian network structure without any structural 
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limitations (Silander & Myllymak) provided us with a fully connected structure. In 
order to further validate the model, the mutually common genes were implemented 
into a Bayesian network that allowed us to determine the probability distribution of 
gene expression (low, normal, & high), location of disease (tissue and blood), and 
vascular state (disease and no disease). Represented by our initial model it was 
predicted that ID3 was predominately expressed as high (high: 79%, normal: 4%, 
& low: 17%). Also the vascular state was in close proximity of one another (disease 
state: 56%, control state: 44%). We demonstrated in the model when ID3 was 
expressed at various levels at 100% (high, normal, & low). Interestingly when ID3 
is highly expressed the genes in the model also became highly expressed 
predominantly occurring in blood with an evenly distributed vascular state 
(disease: 51%, control state: 49%). When ID3 expression is normal, the network 
is modeled more in tissue and the vascular state is principally geared toward 
vascular disease (disease: 65%, control: 35%). Low expression of ID3 represents 
activity principally in tissue toward vascular disease (disease: 66%, control: 34%). 
These changes in the model may elucidate to ID3 regulation that exists in this 
network. Furthermore we extended our analysis of ID3 candidate target genes in 
both blood & tissue and investigated which genes are additionally 
estrogenic/endocrine disrupting chemical associated. Results demonstrated that 
gene DNMT1 is associated with ID3 candidate genes in both blood & tissue and 
PCBs; and genes MCM4 & NDUFA7 are associated with ID3 candidate target 
genes in both blood & tissue and PCB153 & PCB180.  
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Interestingly each of these genes have been known to be involved in various 
vascular diseases through the literature. ABCB6 has been shown to have a new 
role in preventing atherosclerosis growth by inhibiting platelet production, 
reactivity, and chemokine (C-C motif) ligand-5 deposition in atherosclerotic lesions 
(Murphy et al., 2014). ACP1 is identified to be associated with atherosclerosis and 
autoimmune diseases in Caucasians. It was shown that rs79716074 genotype of 
GA polymorphism in ACP1 is associated with decreased risk of coronary arterial 
disease in Chinese northeast population especially in females (Li et al., 2015). 
CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and 
dihydroorotase) has been demonstrated as an unacknowledged mechanism that 
regulates NOTCH/VEGF signaling during angiogenesis (Caxam et al., 2015). 
DCBLD2 which is also known as ESDN has been established as a potential 
diagnostic and therapeutic target for graft atherosclerosis, which still remains a 
cause of progressive, chronic failure in cardiac allograft (Sadeghi et al., 2007). 
MCM4, part of a family of pre-replication complexes show that MCM2, MCM4, and 
MCM7 mRNA levels are increased in VSMCs during G1 phase, as indicated by 
increased Cyclin D1 levels (Guo et al., 2013). Furthermore this family of proteins 
is mutually modified by ID3 influence (MCM2, MCM3 and MCM10), such that 
genes down-regulated in PMEL-1 RAG1−/−ID3−/− T cells were induced by 
overexpression of ID3 (Ji et al., 2011). Also, DNMT1, a differentially expressed 
gene that is associated with VSMC-associated diseases which is regulated by 17 
miRNAs, where these miRNAs are possible targets for developing anti-R based 
miRNA therapy, was recently established (Chen et al., 2017). DHRS3, was 
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recently reported to be associated with rheumatoid arthritis (RA), a complex and 
prevalent complex inflammatory disease primarily affecting the joint (Wang et al., 
2017). The vascular disease in RA encompasses a large spectrum ranging from 
rheumatoid vasculitis to atherosclerotic lesions (Tanasescua et al., 2009). 
NDUFA7, a subunit of the complex-I in the mitochondrial respiratory chain was 
also demonstrated to be associated with rheumatoid arthritis (RA). Association of 
NDUFA7 and RA suggest reactive oxygen species (ROS) in the pathogenesis of 
the disease (Mitsunaga et al., 2015). Additionally we have previously shown that 
ID3 is an important determinant of ROS-induced proliferation of estrogen exposed 
endothelial cells & the overall results suggest ID3 may serve as a beneficial target 
for estrogen-dependent vascular-proliferative diseases (Felty & Porther, 2008). 
We also demonstrated ID3 overexpressing cells which supported the formation of 
a 3-D microvascular lesion co-cultured with smooth muscle cells (Das JK et al., 
2015) and overexpression of ID3 increased neovascularization, cell migration, and 
spheroid growth of human cerebral microvascular endothelial cells, hCMEC/D3 
(Das & Felty, 2015). We postulate that ID3 does have an essential role in regulation 
of these genes that take part in perturbations of vascular-intimal lesions.  
Conclusion 
 
In summary, our analysis strongly indicates that ID3 does have a molecular 
mechanism that affect changes in extracellular matrix, cell adhesion, & cell growth 
which predisposes the blood vessel to vascular dysfunction. Common genes 
identified in blood and tissue samples show a strong suggestion for their several 
roles in vascular diseases.  Therapeutic interventions which aim to target these 
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particular processes may indicate great effectiveness in the treatment and 
prevention of vascular disease.  
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CHAPTER VI 
OVERALL CONCLUSIONS 
The main objective of the findings in this dissertation was to assess the role 
of Inhibitor of DNA-binding/differentiaon-3 (ID3) in vascular diseases with respect 
to its regulation of vascular-intimal lesion formation and explanation of how ID3 
predisposes the vessel to vascular dysfunction & endocrine disrupting pollutants. 
Our approach to bridging gaps between ID3, endocrine disrupting chemicals & 
vascular disease warrants unique work.   
The initial goal addressed in manuscript 1 was utilized as a literature review 
to highlight the current understanding of how ID3 may contribute to multifaceted 
chronic diseases via metabolic perturbations such as cancer, neurological 
disorders, vascular, autoimmune, and bone diseases. Furthermore the existing 
literature suggests chronic exposure to endocrine disrupting chemicals (EDCs) 
within the human body are connected with metabolic disorders, and how the 
influence of these chemicals affect ID3. Also ID3 has the ability to inhibit or 
stimulate gene expression resultant in cellular hyper-proliferation or stemness 
markers. Additionally ID3 has been shown to be in involved in metabolic syndrome 
(MetS) and EDCs mainly focusing on the three conceivable etiological factors such 
as insulin resistance, obesity and adipose tissue disruption, and a group of 
independent factors. We also address ID3 and its involvement in molecular 
mechanisms & signaling pathways that lead to these various disease outcomes.  
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The second aim addressed in manuscript 2 explored the association of 
exposure to an endocrine disrupting chemical (PCBs) and participants diagnosed 
with peripheral arterial disease as well as participants defined with atherosclerosis. 
We analyzed a population 40 years and older with available PCB data from 1999 
– 2004. Exposure assessment was based on lipid adjusted concentrations of 6 
individual PCB congeners (074, 099, 118, 138, 153, and 180), the sum of dioxin-
like PCBs (074+118), and the sum of non-dioxin-like PCBs (099+138+153+180) in 
conjunction with examination data obtained from NHANES. We calculated GMs 
(geometric means) to compare concentrations of PCBs in participants with PAD 
definition, atherosclerosis, and normal participants. GMs of the 6 individual PCB 
congeners were established to be higher among participants with PAD diagnosis 
as well as atherosclerosis when compared to the rest of the study population. The 
overall GM levels of PCBs increased significantly in PAD participants as age group 
progressed except PCB099, which demonstrated a non-consistent trend (10.04 
ng/g vs. 8.82 ng/g vs. 18.99 ng/g). Furthermore consistent trends were shown in 
the first and second age group (≥ 40 – 59) & (60 – 74) years old respectively, 
however in the final age group ≥ 75 only 2 PCB congeners showed higher 
concentration levels in the diseased status compared to the normal and 4 
congeners (099, 138, 153, and 180) shown to have higher PCB GMs in normal 
participants. We also demonstrated adjusted models for PAD confounders; gender 
and PAD confounders; age, race, BMI, and PAD confounders; and gender, age, 
race, BMI, and PAD confounders. All models showed significant association with 
individual PCB congeners and increased risk of PAD when LOD ≥ 50. 
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Furthermore, adjusted models for both dioxin-like and non-dioxin-like PCBs also 
demonstrated significant association with higher exposure and increased risk of 
PAD.   
We further extended the second aim in manuscript 3 by exploring the 
association between additional types of endocrine disrupting chemicals 
(phthalates, BPA) with PAD. GM levels demonstrated higher levels of phthalate 
metabolites: MnBP and MBzP in participants diagnosed with PAD and AS when 
compared to the rest of the population. Furthermore GM levels of BPA was shown 
to be higher in participants diagnosed with PAD and AS when compared to normal 
participants. Adjusted models for PAD confounders; gender and PAD 
confounders; age, race, BMI and PAD confounders; and gender, age, race, BMI, 
and PAD confounders demonstrated significant association with PAD and higher 
exposure of phthalate metabolites (≥ LOD) as well as BPA (≥ LOD). PAD 
confounder adjusted models showed significant association with phthalate 
metabolites: MnBP (OR: 1.33; 95% CI: 1.00 – 2.34) and MBzP (OR: 1.16; 95% CI: 
1.08 – 5.07). Additionally PAD confounder adjusted model also demonstrated 
significant association with BPA (OR: 1.22; 95% CI: 1.02 – 5.07). Adjusted model 
for gender and PAD confounders showed significant association with phthalate 
metabolites: MnBP (OR: 1.83; 95% CI: 1.00 – 2.34), MCHP (OR: 1.54 95% CI: 
1.00 – 2.10), MEP (OR: 1.01; 95% CI: 0.44 – 1.09), and MBzP (OR: 1.76; 95% CI: 
1.58 -2.91) as well as BPA (OR: 2.89; 1.50 – 10.19). Age, race, BMI, and PAD 
confounders adjusted model demonstrated significant association with phthalate 
metabolites: MnBP (OR: 1.33; 95% CI: 0.89 - 2.95), MCHP (OR: 1.39; 95% CI: 
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1.00 -1.65), MiBP (OR: 1.48; 95% CI: 1.12 – 1.87) alongside BPA (OR: 2.17; 95% 
CI: 1.65 – 7.15). The final model with gender, age, race, BMI, and the PAD 
confounders demonstrate MCHP (OR: 1.34; 95% CI: 1.22 – 1.59), MiBP (OR: 1.41; 
95% CI: 0.99 – 1.83), MBzP (OR: 1.73; 95% CI: 0.92 – 3.18) alongside BPA (OR: 
3.02; 95% CI: 0.14 – 12.15) showed significant association with higher exposure.  
The aim addressed in manuscript 4 investigated the role of ID3 and ID3 
candidate target genes in vascular diseases in respect to elucidating the specific 
focus of how ID3 plays a role in vascular-intimal lesion formation. ID3 has been 
previously shown to be important to the embryonic vasculogenesis and endothelial 
cell activation. Additionally it has been shown in various vascular disease 
mechanisms such as neo-intimal formation, VSMC growth, visceral adipose 
VEGFA expression, & increased endothelial cell neovascularization. We compiled 
microarray expression data using NCBI GEO on vascular diseases. Using 
computational analysis such as pearson correlation & independent t-test we 
identified ID3 candidate targets in blood and tissue respectively. We identified 217-
candidate target genes in blood and 134-candidate target genes in tissue. Gene 
ontology methodology further supported us to explore the role of the identified ID3 
candidate target genes in blood and tissue samples (217 and 134 respectively). 
Overlapping genes in both blood and tissue were furthermore identified and 
include: ABCB6, ACP1, BYSL, CAD, CDH15, DCBLD2, DHRS3, DNMT1, ID3, 
MCM4, and NDUFA7. Utilizing Bayesian network structure without any structural 
limitations provided us with a fully connected structure validating an interactive 
model. Furthermore we implemented those same genes using Genie to allow us 
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to determine probability distribution of gene expression within the network. Our 
initial model predicted ID3 to be predominately expressed high (79%) with the 
vascular state of the disease being in close proximity of one another (disease state: 
56%, control state: 44%). Interestingly these mutually represented genes in both 
blood and tissue have been demonstrated in various vascular diseases throughout 
the literature such as atherosclerosis and vascular pathology of rheumatoid 
arthritis.  
In conclusion, the major findings from the research conducted in this 
dissertation indicate a number of results. We investigated the role of endocrine 
disrupting chemicals (PCBs, phthalates, and BPA) and their association with 
vascular disease (PAD). Our findings show higher PCB, specific phthalate 
metabolites, and BPA concentrations in participants diagnosed with PAD as well 
as those with atherosclerosis when compared to the normal population. 
Furthermore, adjusted models demonstrated significant association with higher 
exposure to these endocrine disrupting chemicals and increased risk of PAD. ID3 
may play a role in regulating certain genes in vascular diseases that take part in 
different biological processes that are significant drivers in the growth of vascular-
intimal lesions such as cell adhesion, extracellular matrix, & cell growth. These 
genes include: ABCB6, ACP1, BYSL, CAD, CDH15, DCBLD2, DHRS3, DNMT1, 
ID3, MCM4, and NDUFA7. Overall, the exposure to EDCs particularly to vascular 
disease may contribute to the underlying understanding of how the mechanism of 
ID3 regulates certain genes that are essential components of the growth of 
vascular-intimal lesions. 
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Limitations  
 There were a number of limitations to our study. For our NHANES study 
since it was a cross sectional design it does not allow for casual interpretations 
due to self-reported data. Self – reported data increases the likelihood of 
misclassification bias of cases and controls contributing to the risk of incorrectly or 
undiagnosed reported PAD and/or AS cases. Furthermore, missing data also limits 
the overall finding of our study. Additionally, observed associations could be 
potentially confounded due to lack of information. For our GEO study not all 
dataset characteristics were represented which could lead to bias with various 
variables.  
Future Studies 
Although our findings should be viewed upon with thoughtfulness, they 
indicate that research involving the complex combination of environmental & 
molecular determinants should warrant further consideration. Additional research 
needs to be completed in order to account for the vast intricacy of how these types 
of determinants can change the development of not only vascular diseases but 
chronic diseases such as cancer and neurological disorders. The combined effects 
of EDCs and their influence on the molecular mechanisms that affect disease 
outcomes should be evaluated at a more complete perspective. Widespread 
exposure to EDCs and overall concern for growth in vascular disease risk, 
especially with sensitive molecular & genetic mechanisms permits a strong need 
for further research.  
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